State and municipal people’s governments, provincial committees, offices, departments and bureaus:

"Yunnan Province" 14 th Five-Year Plan "for the Innovation and Development of Biomedical Industry has been agreed by the provincial people’s government and is hereby issued to you, please implement it carefully.

General Office of Yunnan Provincial People’s Government

March 17, 2022

(This piece is publicly released)

In order to accelerate the innovation and development of the biomedical industry, this plan is formulated according to the 14th Five-Year Plan for National Economic and Social Development in Yunnan Province and the Outline of Long-term Objectives for the Year 2035, combined with the reality of our province.

I. Development Status and Situation

(A) Development effectiveness

During the "Thirteenth Five-Year Plan" period, the provincial party committee and the provincial government conscientiously implemented the spirit of the important speech of the Supreme Leader General Secretary on his inspection of Yunnan, and on the basis of continuously building eight key industries and world-class "three cards", put forward the strategic deployment of focusing on cultivating five trillion-level pillar industries and eight billion-level advantageous industries and building a modern industrial system. Biomedical industry, as a strategic emerging industry with a focus of 100 billion yuan in our province, has steadily expanded its scale, significantly enhanced its innovation ability, increasingly optimized its policy environment, and continuously improved its economic benefits. Its operating income increased from 124.109 billion yuan in 2015 to 252.145 billion yuan in 2020, with an average annual growth rate of 15.23%, and its added value increased from 36.587 billion yuan in 2015 to 73.14 billion yuan in 2020. The average annual growth rate reached 14.86%, the business income and added value doubled, and a research and production system of biotechnological drugs focusing on vaccines was gradually formed, and a whole industrial chain development system of natural drugs (ethnic Chinese medicines) featuring proprietary Chinese medicines, Chinese herbal pieces, extracts and health products was established.

In 2020, the province’s Chinese herbal medicine planting (breeding) industry will realize an operating income of 51.611 billion yuan; The biomedical manufacturing industry realized an operating income of 59.592 billion yuan; The biomedical commerce and trade industry realized an operating income of 140.942 billion yuan. There are 163 pharmaceutical manufacturing enterprises above designated size (including 1 enterprise with operating income exceeding 10 billion yuan and 5 enterprises with 1-10 billion yuan). There are 48 varieties with sales income exceeding 100 million yuan (including 5 varieties exceeding 1 billion yuan and 4 varieties with 500-1 billion yuan). Up to now, there are 9 biomedical enterprises listed on the main board and growth enterprise market in the province.

1. The biotechnology pharmaceutical industry has made breakthrough development.

In 2020, the province’s biological products manufacturing industry above designated size represented by vaccines achieved an operating income of 5.357 billion yuan, accounting for 15.6% of the operating income of pharmaceutical manufacturing industry above designated size. There are 13 vaccine varieties on the market, and the operating income of vaccine enterprises has increased from 800 million yuan in 2009 to 4.8 billion yuan in 2020, and the biotechnology drug industry has made breakthrough progress. The inactivated enterovirus 71 vaccine independently developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences was launched in December 2015, and the annual operating income of a single variety was nearly 2 billion yuan. The 23-valent pneumococcal polysaccharide vaccine developed by watson biological was launched in July 2017, with an operating income of 688 million yuan in 2020; The first trivalent pneumococcal polysaccharide conjugate vaccine in China and the second trivalent pneumococcal polysaccharide conjugate vaccine in the world went on the market in April 2020, with an operating income of 1.658 billion yuan in the first year, and the market prospect is considerable. Some traditional pharmaceutical companies and scientific research units have accelerated the layout and development of biotechnological drugs. Suparutide injection, a long-acting hypoglycemic drug developed by Kunyao Group, has obtained clinical approval, and Sino Pharmaceutical has carried out research on new drugs of humanized CD22 antibody immunotoxin 1.1.

2 Chinese medicine (ethnic medicine) industry scale

In recent years, the traditional Chinese medicine (ethnic medicine) industry in our province has become the main force to promote the development of biomedical industry from small to large and from weak to strong. 60 "Hometowns of Yunyao" and 103 "Pharmaceutical Parks" have become the new force to improve the quality and brand of Chinese herbal medicines. In 2020, the main business income of planting (breeding) and product processing of Chinese herbal medicines in the province will exceed 100 billion yuan, among which the processing and manufacturing of Chinese herbal medicines above designated size, such as proprietary Chinese medicines, Chinese herbal pieces, extracts and health products, will achieve an operating income of about 48 billion yuan, accounting for over 80% of the main business income of biomedical industries above designated size. The planting area of Chinese herbal medicines exceeds 9 million mu, the planting area of 15 varieties of Chinese herbal medicines, such as Panax notoginseng, Paris polyphylla, Dendrobium, Amomum villosum and Radix Aucklandiae, exceeds 100,000 mu, and the standardized planting base of Chinese herbal medicines covers an area of 1.46 million mu, including 22,000 mu of green certification base and 126,000 mu of organic certification base. Sanqi, Erigeron breviscapus industry has formed a whole industrial chain layout of planting, processing, R&D and production, which has played a very prominent role in demonstrating the development of traditional Chinese medicine industry in the province. Panax notoginseng industry has achieved standardization and standardized planting, and developed relatively complete back-end products such as decoction pieces, preparations and health products, which has become a big variety second only to ginseng. The planting area of the whole province is about 400,000 mu, and the agricultural output value is about 6 billion yuan. A number of Chinese patent medicines and injections such as Panax notoginseng decoction pieces, Xuesaitong soft capsules, Xuesaitong for injection (freeze-dried powder injection), Xuesaitong tablets, Xuesaitong capsules, Panax notoginseng saponins and Xuesaitong injection, etc.

3. The chemical medicine industry has developed steadily.

In 2020, the chemical preparation manufacturing industry and the chemical raw material medicine manufacturing industry above designated size will realize an operating income of 3.52 billion yuan, accounting for 10.2% of the pharmaceutical manufacturing industry above designated size. Initially gathered a number of chemical pharmaceutical enterprises such as Jida Pharmaceutical, Baker Norton, Haobang Pharmaceutical, Sino Pharmaceutical, Longhai Pharmaceutical and Guiyan Pharmaceutical; Longjin Pharmaceutical, Haobang Pharmaceutical and Plant Pharmaceutical cooperated with Indian generic drug companies to actively introduce Indian generic drug varieties to Yunnan; Nine varieties, including amoxicillin capsules, chlorphenamine maleate tablets and ambroxol hydrochloride injection, passed the consistency evaluation of chemical generic drugs.

4. Remarkable achievements have been made in biomedical science and technology innovation.

Driven by scientific and technological innovation, the biomedical industry has gradually embarked on a high-quality development track. Sabin inactivated poliomyelitis vaccine, EV71 inactivated enterovirus vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine and other fist products have been listed one after another, and some varieties are undergoing WHO pre-certification; Covid-19 inactivated pneumonia vaccine, F gene mumps live attenuated vaccine, nine-valent human papillomavirus (HPV) vaccine, rotavirus inactivated vaccine and tetravalent meningococcal polysaccharide conjugate vaccine are in the clinical research stage, which has provided strong support for the rapid development of the vaccine industry during the Tenth Five-Year Plan. Ten innovative drugs, such as KPCXM18, a natural medicine for treating ischemic stroke, Duanjin Jiedu Capsule, a 6-class Chinese medicine, Suparutide injection, and a 1.1-class new drug of bungarus multicinctus venom, were approved by the national drug clinical approval. Winona series products, with authentic Yunnan medicinal materials as the main raw materials, have developed into an important functional skin care brand in China. "Key Technology Creation and Industrial Application of Comprehensive Development of Panax notoginseng" won the second prize of National Science and Technology Progress Award, "Key Technology and Application of Standardization and Industrial Development of Panax notoginseng" won the first prize of Yunnan Science and Technology Progress Award, and three standards of Panax notoginseng, seeds and seedlings and Gastrodia elata passed the international quality standard certification. Panax notoginseng saponins and breviscapine have passed GRAS (generally considered safe) certification recognized by FDA, and entered the catalogue of American botanical medicine raw materials;Tongshu capsule and Xuesaitong soft capsule were approved by FDA to carry out phase II clinical research.

Around the great demand of the development of biomedical industry, a number of R&D service platforms have been built, such as Yunnan Biovaccine Technology Innovation Center, Yunnan Drug Non-clinical Safety Evaluation Research Center, Yunnan Natural Drug Activity Screening and Evaluation Center, Yunnan Stem Cell and Regenerative Medicine Research Center, Yunnan Flower Aromatic Health Products R&D Center, and Yunnan Chinese Medicine Seed Breeding R&D Center. By the end of the 13th Five-Year Plan, there were 47 provincial key laboratories in the biomedical field, 20 engineering technology research centers, 19 engineering research centers, 10 clinical medical research centers and 4 academicians of the two academies in the province, and 12 provincial science and technology leaders were trained, 54 provincial high-level talents were introduced, 4 high-level innovation and entrepreneurship teams were introduced, 553 provincial young and middle-aged academic and technological leaders and 553 provincial innovative talents were trained.

5. Bio-pharmaceutical industry has achieved initial results by attracting big and strong players.

Yunnan Baiyao Group introduced social capital to complete the mixed reform, and the development of the group entered the fast lane; China Resources Sanjiu acquired Kunming Shenghuo Pharmaceutical, and the company’s operating income increased significantly; Guizhou Bailing invested in Yunnan plant pharmaceutical industry, focusing on characteristic products, optimizing product structure, and implementing large-variety brand strategy. The scale of the enterprise has maintained rapid growth for many years. Well-known enterprises inside and outside the province, such as Sinopharm Group, Shanghai Pharmaceutical Group, Guangzhou Pharmaceutical Group, Tasly Pharmaceutical, Kangenbei Pharmaceutical, Shenwei Pharmaceutical, New Green Pharmaceutical, Beijing Tongying, Fangsheng Pharmaceutical, Jilin Xingshen, Hong Kong Juzhang and Shenzhen Botton, have landed in Yunnan and actively participated in the healthy development of the biomedical industry.

(B) Advantages and shortcomings

1. Location advantage

Yunnan has outstanding geographical advantages. It is adjacent to Guizhou and Guangxi in the east, Sichuan in the north, Tibet in the northwest, and Myanmar, Laos and Vietnam in the west and south. It is an important channel connecting South Asia, Southeast Asia and the Indian Ocean region, and an important intersection of the "Belt and Road" construction and the national development strategy of the Yangtze River Economic Belt. The biomedical industry has a huge potential market, which can be built on the basis of vaccines and traditional Chinese medicine (ethnic medicine)

2. Resource advantages

Yunnan has obvious three-dimensional climate characteristics, many types, beautiful mountains and rivers, pleasant climate and outstanding biodiversity characteristics. It is known as the "plant kingdom", "animal kingdom", "microbial kingdom", "hometown of medicinal materials" and "treasure house of biological genes", and is the province with the richest biological resources, natural medicines and ethnic medicine resources in China. According to the statistics of the third national survey of traditional Chinese medicine resources, there are 6,559 kinds of traditional Chinese medicine resources in the province, accounting for 51.4% of the total number of kinds in the country, more than 2,000 kinds of ethnic medicine resources and more than 10,000 folk prescriptions.

3. Advantages of industrial base

Notoginseng Radix, Rhizoma Paridis Yunnanensis, Erigeron breviscapus, Dendrobium candidum, Fructus Amomi, Rhizoma Gastrodiae, Poria Yunensis, Radix Angelicae Sinensis, Radix Aucklandiae, Radix Gentianae Yunnanensis and other "Top Ten Yunyao" brand medicinal materials have excellent quality and are widely recognized in the industry. It has built a domestic raw material base for high-quality natural medicines and health products. The large varieties of Yi medicine represented by Yunnan Baiyao, the unique ethnic medicines such as Dai and Naxi, and the unique ethnic medical technologies such as Dai medicine, which are in the same strain as the traditional medical systems of neighboring countries, provide rich ethnic medical resources for the innovation, inheritance and development of traditional Chinese medicine and the opening up of markets for South Asian and Southeast Asian countries. Gu Fangzhou, known as the "father of polio vaccine in China", engaged in the research of live attenuated polio vaccine in Yunnan, established the method of isolation and finalization of polio virus, formulated the trial production and safety standards of live polio vaccine, and formulated the "Rules for the manufacture and verification of live polio vaccine", which guided the production and identification of billions of vaccines in China and laid a solid foundation for the rapid development of vaccine industry in our province.

4. Shortcomings of rapid industrial development

First, the industry is small in scale and weak in competitiveness. The overall scale of Yunnan’s biomedical industry is small. Among the top 500 main business incomes of the national pharmaceutical industry, there are only 10 in Yunnan. The overall competitiveness of the biomedical industry, which is dominated by traditional Chinese medicine, is weak, especially affected by the national medical reform policies such as the catalogue of auxiliary drugs of traditional Chinese medicine, the catalogue of medical insurance, and the consistency evaluation of traditional Chinese medicine injections. The scale of biomedical manufacturing industry has declined slightly for two consecutive years.

Second, the industrial structure is not excellent and the industrial chain is incomplete. The development of standardized planting (breeding) bases of Chinese herbal medicines lags behind, the phenomenon of small varieties of Chinese herbal medicines is prominent, the research foundation is uneven, and the competitiveness of products is generally weak; Vaccines are the main biotechnological drugs, but the pipelines of antibody drugs, biological similar drugs, cell products, blood products and other products are not rich, and the upstream and downstream supporting industries are basically blank; Small amount of chemicals, lack of original research drugs and high-end generic drugs; The development level of medical devices and veterinary drugs is low.

Third, the core competitiveness of enterprises is weak, and the degree of specialization of the park is low. There are few well-known enterprises and leading enterprises, leading enterprises are not aware of advanced layout and innovative R&D activities, and the industry is not leading enough; Insufficient investment in research and development, lack of influential and innovative varieties, and weak core competitiveness; The level of professional development of biomedical industrial park is not high, the supporting system is not perfect, and the public R&D and service capabilities are weak.

Fourth, innovation ability is not strong, and high-level talents are lacking. The research and development system of new drug creation is imperfect, the resources are scattered, and the technical level is not high, which does not match the needs of the industrial chain; Lack of forward-looking scientific research ability for common technologies, key technologies and cutting-edge technologies needed for rapid industrial development; There are few innovative products in other industries except vaccines; The linkage between enterprises and scientific research institutions is not close, and the contradiction between supply and demand in the transformation of scientific and technological achievements is prominent; Lack of high-level R&D innovation centers and insufficient public R&D service platforms such as drug safety evaluation (GLP), drug clinical evaluation (GCP) and contract R&D institutions (CRO); There is a serious shortage of high-level innovative talents, management talents and teams.

Fifth, brand building is not enough, and market development ability is weak. Enterprises are weak in coping with industrial policies such as medical reform, drug review and approval, and drug production supervision, and weak in market cultivation and brand building of their own products; There is a lack of systematic publicity highlighting the advantages and characteristics, insufficient excavation of superior Chinese herbal medicine varieties, time-honored traditional Chinese medicine and ethnic medicine culture, and weak brand building and market promotion of "Yunyao".

(3) Opportunities and challenges

1. Health needs are increasing.

With the increase of sub-health population and the acceleration of population aging, people’s demand for health products has increased rapidly; The demand for health consumption has changed from medical treatment to disease prevention, health care and health promotion; The national new medical reform plan puts the prevention and control of diseases in the first place, and pays more attention to "preventing diseases before they occur". Traditional Chinese medicine (ethnic medicine) will be promising.

2. Building a domestic and international dual cycle will bring new opportunities for industrial development.

The COVID-19 epidemic has had a great impact on the global industrial chain and supply chain. It is an inevitable requirement to maintain a stable and healthy economic development by adjusting the economic development path, opening up the international circulation, smoothing the domestic circulation, coordinating development and security, enhancing the autonomy, sustainability and resilience of economic development. Seize the development opportunities brought by the Regional Comprehensive Economic Partnership Agreement (RCEP), make full use of Yunnan’s geographical advantages in connecting South Asia, Southeast Asia and the Indian Ocean region, and exchange the traditional medicine with neighboring countries, realize the smooth connection with the biomedical industry in South Asia and Southeast Asia, and accelerate the construction of a new international and domestic dual-cycle development pattern.

3. The epidemic situation in COVID-19 affected the development pattern of pharmaceutical industry.

After the outbreak of COVID-19, COVID-19’s vaccine research and development and production have become the focus of international competition in the field of biotechnology drugs, which puts forward new requirements for the corresponding research and development technology system, experimental evaluation, manufacturing capacity level and organizational management efficiency. With the development of modern biotechnology such as genetic engineering, cell engineering, tissue engineering, biosynthesis, bioinformatics and precision medicine, biotechnological drugs such as vaccines and antibody drugs have become the main direction of the transformation and upgrading of the biomedical industry. The competitive advantages of prescription and medicine represented by "three drugs and three parties" are prominent, and the modern innovative Chinese medicine with clear mechanism of action and definite clinical effect has obvious competitiveness. The demand for medical materials represented by ventilators, testing reagents, medical masks and protective clothing has surged, which has promoted the development of the medical device industry.

4. Competition in domestic pharmaceutical industry is becoming increasingly fierce.

All provinces (autonomous regions and municipalities) take biomedicine as a priority industry, and Beijing, Shanghai, Jiangsu, Guangdong and other provinces (municipalities) have been at the forefront of the country by virtue of their own geographical, policy, talent and technical advantages; Shandong, Sichuan, Hubei, Jiangxi and other provinces have also accelerated the pace of industrial development, and the competition between regions has become increasingly fierce. The reorganization of enterprises in the industry is frequent, and super-large enterprises are constantly emerging. The development trend of agglomeration is obvious, full of opportunities and challenges.

5. The medical reform policy forces the pharmaceutical industry to develop with high quality.

The research and development, production and sales of pharmaceutical products are highly dependent on policy factors, and the industrial development is deeply influenced by policy regulation. The continuous adjustment of various policies, such as drug supervision, the catalogue of traditional Chinese medicine auxiliary drugs and the new medical insurance catalogue, has prompted pharmaceutical enterprises to increase investment in research and development, take a higher quality development path, change from extensive development to refined development mode, and change products from imitation to original innovation. At the same time, information technology represented by mobile medical care, cloud computing, big data and Internet of Things has begun to penetrate into all aspects of the biomedical industry.

6. Competition for innovative drugs has intensified.

At present, the research and development of major innovative drugs are still led by well-known multinational companies, and the competition for technology, talents and funds in the biomedical industry is extremely fierce. Large pharmaceutical companies focus on developing innovative drugs for clinical value in the fields of biotechnology drugs and chemical drugs, while expanding new indications of existing products and expanding upstream and downstream business chains. Pharmaceutical companies with obvious competitive advantages in core products, diversified products and outstanding R&D capabilities will have stronger competitiveness and anti-risk ability. The global vaccine industry presents an oligopoly pattern, with the top 10 companies accounting for 95.7% of the total vaccine market share, and the four vaccine giants GSK (GlaxoSmithKline), Merck, Sanofi and Pfizer accounting for about 80% of the total market share. In the future, the global vaccine market has great growth potential and will grow rapidly with a compound annual growth rate of 10%. The rapid development of frontier technologies such as gene therapy and cell therapy is expected to form major innovative drugs and new supporting technologies. The patents of the top 10 original drugs in global sales, such as Hummel, Merlot and Avastin, are about to expire, and generic drugs and bio-similar drugs are expected to usher in new opportunities. From the national situation, the major achievements of new drug research and development are mainly concentrated in Beijing, Shanghai, Jiangsu and other places, and innovative enterprises led by new drug research and development, such as Hengrui Pharma and Wuxi PharmaTech, have a strong development momentum.

Second, the development ideas, principles and objectives

(A) development ideas

Guided by the Supreme Leader’s Socialism with Chinese characteristics Thought in the New Era, we will fully implement the spirit of the 19th National Congress of the Communist Party of China and the previous plenary sessions of the 19th National Congress, thoroughly study and implement the spirit of the important speech of the Supreme Leader’s General Secretary on his visit to Yunnan, conscientiously implement the decision-making arrangements of the provincial party committee and government, grasp the new development stage, implement the new development concept, serve and integrate into the new development pattern, adhere to the problem-oriented, goal-oriented and result-oriented, take innovation as the core, quality as the foundation, and take enterprises as the main body. Market-oriented, focusing on the three key areas of biotechnological drugs, modern Chinese medicine and health products, we will focus on attracting investment accurately, strengthening the main body of enterprises, enhancing innovation ability, building industrial clusters, promoting industrial development with engineering measures, building domestic first-class R&D and production bases of biological vaccines and modern Chinese medicine, domestic top-quality raw materials bases of natural drugs and health products, and biomedical trade bases facing South Asia and Southeast Asia, forming an industrial cluster with important influence in the country, and realizing the high-quality development of Yunnan biomedical industry.

(2) Basic principles

1. Innovation-driven, quality-improved development

Around the industrial chain, deploy innovation chain, build a batch of high-level public service platforms and professional R&D platforms, break through a batch of technologies, reserve a batch of achievements, develop a batch of products and transform a batch of achievements, and promote the high-quality development of Yunnan biomedical industry.

2. Based on advantages and outstanding features

Based on the advantages of Yunnan’s location, ecology, environment, resources and nationality, we will highlight the characteristics of biological vaccines, authentic medicinal materials, ethnic medicine, classic and famous prescriptions, proven prescriptions and cell technology, strengthen product quality and standards, and accelerate industrial transformation and upgrading.

3. Government guidance and market dominance

Innovate institutional mechanisms, rationally allocate resources, break through policy bottlenecks, cultivate and expand market players, release enterprise vitality and market potential, and build a sound market system and policy system.

4. Open cooperation and push forward together.

Improve the soft and hard environment, expand the domestic and foreign markets, and support local enterprises to become bigger and stronger; Introduce well-known enterprises and scientific research achievements to expand the increment; Attracting scientific research institutes from outside the province to develop in Yunnan, jointly cultivating talents, focusing on R&D and innovation, and forming a strong synergy to promote industrial development.

(III) Overall objectives

By 2025, the operating income of the biomedical industry will achieve the goal of "ensuring four guarantees and competing for five", that is, it will reach 400 billion yuan and strive to reach 500 billion yuan, with an average annual growth rate of more than 10%. Among them, the biomedical manufacturing industry will achieve an operating income of more than 150 billion yuan, with an average annual growth rate of more than 20%. The added value of biomedical industry reached 120 billion yuan, with an average annual growth rate of more than 10%. Strive for the biological vaccine industry to achieve the number and value of batch issuance. Facing 2035, we will focus on key markets, increase promotion, actively tap the domestic market, vigorously explore the South Asia and Southeast Asia markets, further enhance the influence and market share of the brand "Yunyao", and build Yunnan into a biomedical R&D innovation and product production and trade center with distinctive characteristics of serving the whole country and radiating South Asia and Southeast Asia, and build an industrial cluster with important influence in the country.

-do it on a large scale. By 2025, we will cultivate more than one enterprise (group) with operating income exceeding 50 billion yuan, more than five enterprises (groups) exceeding 10 billion yuan, more than five enterprises (groups) exceeding 5 billion yuan, more than 20 enterprises (groups) exceeding 1 billion yuan and more than 70 enterprises exceeding 100 million yuan.

-strengthen varieties. By 2025, more than 10 varieties with sales income exceeding 1 billion yuan and more than 60 varieties with sales income exceeding 100 million yuan will be cultivated.

-do an excellent structure. By 2025, the leading development of biotechnological drugs will be realized, modern Chinese medicine (ethnic medicine) will be upgraded and developed, dual-use products for medicine and food will develop by leaps and bounds, and chemical drugs and medical devices will make breakthroughs.

-fill in the short board. We will build and upgrade a number of public R&D and service platforms around biotechnology drugs, modern Chinese medicine and chemical drugs, break through a number of key core technologies, and develop a number of competitive and innovative products.

Third, key tasks

Around the biomedical industry chain, deploy innovation chain, promote the organic integration of industry chain and policy chain, innovation chain, capital chain, supply chain, talent chain and value chain, focus on key core technologies, fill the shortcomings of the platform and increase high-quality varieties. Strengthen leading enterprises and enhance manufacturing capacity. Optimize the industrial layout, strengthen the construction of the park, and form industrial agglomeration. Enhance the brand of "Yunyao", revitalize the stock, introduce increments, expand the total amount, and realize the high-quality development of the biomedical industry.

(1) Strengthen varieties and accelerate the transformation and upgrading of biomedical manufacturing.

Give priority to the development of biological vaccines, modern Chinese medicines (ethnic medicines), Chinese herbal pieces and chemical medicines, vigorously develop biotechnological medicines such as antibody medicines, gene technology, cell therapy and blood products, as well as health products, detection and diagnosis reagents, medium and high-end medical devices, strengthen the research and innovation of biotechnological medicines, modern Chinese medicines, natural medicines, generic medicines, new preparations and health care products, and support the internationalization of vaccines, modern Chinese medicines and medical devices. Focusing on increasing investment in scientific and technological innovation, building a number of well-known enterprises and brand products, introducing large enterprises and groups, encouraging enterprises to acquire and merge, and promoting international development, we will promote digital and intelligent manufacturing and accelerate the transformation and upgrading of biomedical manufacturing.

1. Key development areas

(1) Biotechnology drugs focusing on vaccines

The biotechnology pharmaceutical industry focusing on vaccines is the fastest-growing field in the biomedical industry in our province, and efforts should be made to improve the upstream and downstream industrial chains, enhance the research and development capacity of new vaccines, accelerate the construction of a rapid response system for major infectious diseases, strengthen frontier basic research, and enrich product pipelines.

Focus on Kunming and Yuxi to build biotechnology pharmaceutical industrial bases focusing on vaccines, and vigorously develop new biological vaccines, antibody drugs, biological analogues, cell preparations, blood products such as albumin, coagulation factors and immunoglobulin, and other new products of proteins, peptides and nucleic acids. Enlarge and strengthen the existing biotechnology drug enterprises, encourage vaccine enterprises to build digital and intelligent production lines, and improve the production technology level. Guide enterprises in the province to build, acquire and merge R&D institutions at home and abroad, build a quality system, R&D system and production technology system that are in line with international standards, promote the international registration and WHO pre-certification of biological vaccine products, build a vaccine production and supply base that meets international quality standards and a leading domestic monoclonal antibody drug industry base, increase open cooperation with South Asia, Southeast Asia, Africa, Europe and the United States, and open up markets in South Asia, Southeast Asia and the Indian Ocean Rim.

Traditional vaccines: enterprises are encouraged to develop univalent vaccines, multivalent vaccines and multiplex vaccines with attenuated, detoxified and inactivated products based on pathogenic microorganisms and their metabolites, so as to promote the secondary development and upgrading of biological vaccines.

New vaccines: break through the key core technologies such as efficient genetic engineering construction technology of virus species and strains, screening research technology of pathogen antigen components, bacterial polysaccharide-protein binding technology, large-scale animal cell culture technology, new vaccine adjuvant technology, genetic engineering technology, genetic engineering recombination technology, non-human primate model evaluation, and carry out research and development and transformation of new vaccines such as nucleic acid vaccine, synthetic peptide vaccine, genetic engineering vaccine and recombination vaccines. Increase the forward-looking research and development of mRNA technology in the prevention and treatment of infectious diseases, AIDS, genetic diseases, rare diseases, tumors and other major diseases.

Antibody, protein and nucleic acid drugs: develop monoclonal antibody drugs, neutralizing antibodies, bispecific antibodies, antibody-coupled drugs (ADC), biological analogues, recombinant protein drugs, polypeptide drugs and nucleic acid drugs for diseases such as tumor, immune system, cardiovascular and cerebrovascular diseases and infections.

Animal vaccines: Encourage the research and development of veterinary vaccines such as Class A epidemic vaccines, multi-animal co-morbid vaccines, vaccines for cattle and sheep, vaccines for pigs, vaccines for poultry, and vaccines for pets.

Cell preparation: within the scope permitted by policies and regulations, encourage and standardize the research and development of cell therapy products including stem cells and immune cells; We will carry out research on a series of standards and technical systems such as preparation, quality inspection and safety evaluation of clinical-grade cell products and derivatives, improve their safety, effectiveness and quality controllability, and accelerate the research on clinical application norms of cell therapy.

Blood products: introduce and develop blood products, focusing on the development of coagulation factors, thrombin, human albumin, human fibrinogen, immunoglobulin and other products. Within the scope permitted by the policy, the layout of plasma raw materials will be increased by adding plasma collection stations.

Other biotechnologies: Accelerate the construction of a synthetic biotechnology innovation system, support the research on genome design and synthesis, and provide technical support for basic research on new biological treatment methods, vaccines, materials and disease control.

Make use of the advantages of genetic resources in our province to develop the biomedical industry of non-human primates and carry out research on the protection and rational utilization of human genetic resources; Carry out research on transplant organ cultivation technology and xenotransplantation technology.

(2) Modern Chinese medicine represented by formula granules.

Focus on the quality upgrade, secondary development, new indications mining, economic evaluation, clinical value-oriented research on safety and clinical efficacy evaluation of traditional Chinese medicine, and innovative drug development of traditional Chinese medicine, and make efforts in the research on local standards of characteristic Chinese herbal pieces, quality standards that meet the requirements of Pharmacopoeia, effectiveness and safety evaluation, production process improvement, and automation, intelligence and information construction of production and processing.

Focus on Kunming, Yuxi, Chuxiong, Dali, Wenshan, Baoshan, Pu ‘er, Honghe and other cities to develop modern Chinese medicine. On the basis of medicinal animal and plant resources such as Panax notoginseng, Erigeron breviscapus, Gastrodia elata, Paris polyphylla, Periplaneta americana, leech, etc., and taking the development of characteristic ethnic medicines such as Yi medicine and Dai medicine as a breakthrough, we will speed up the cultivation of large varieties of modern Chinese medicine (ethnic medicine) preparations, create a number of brand products, and make Yunnan medicine industry bigger and stronger. Based on classic prescriptions, proven prescriptions and hospital preparations, we will develop innovative Chinese medicine (ethnic medicine) and epidemic prevention preparations covering the whole life cycle of prevention, treatment and rehabilitation for the prevention and treatment of major diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, emerging infectious diseases and AIDS. Guided by clinical value, we will carry out material basic research, safety evaluation of traditional Chinese medicine and clinical efficacy research, and explore the construction of a three-in-one evidence system of "Chinese medicine theory-human experience-clinical trial" for the research and development of new traditional Chinese medicine. Adopt modern biotechnology, advanced pharmaceutical technology and preparation technology to promote the application of biocatalysis and transformation, refining, extraction and separation in the research and development of modern Chinese medicine.

In Kunming, Chuxiong, Wenshan, Zhaotong, Pu ‘er, Baoshan, Lijiang and other major producing areas, the production base of Chinese herbal pieces will be laid out, with the focus on building Chuxiong into a national first-class industrial base of Chinese herbal formula granules. Form more than 10 brand enterprises producing Chinese herbal pieces and local standards for formula granules of more than 100 varieties. Strengthen cooperation with state-level research institutions and well-known domestic enterprises, carry out research on quality standards of traditional Chinese medicine formula granules and upgrade the processing and production technology, and establish a quality standard system, a safety evaluation system and a clinical trial research system for traditional Chinese medicine decoction pieces that meet the requirements of People’s Republic of China (PRC) Pharmacopoeia and international standards. Carry out the equivalent test and production technology research of formula granules, and establish the processing technology and quality evaluation method of traditional Chinese medicine decoction pieces combined with modern science and technology. Develop new modern technologies, equipment and facilities such as extraction, concentration, drying and granulation, apply blockchain traceability technology to improve online quality control, establish a traceability system for processing and production of Chinese herbal pieces, and build a number of intelligent production lines of Chinese herbal pieces with advanced technology and strict quality control.

We will build a research center for ethnic medicine focusing on Yi medicine, Dai medicine and Tibetan medicine, systematically excavate and sort out ethnic medicine documents of Yi, Dai, Tibetan, Naxi, Wa and Hani nationalities, and carry out clinical application of traditional ethnic medicine therapy and its ancillary products and theoretical research on ethnic medicine. Relying on ethnic medicine resources, develop external preparations. Strengthen the research and development and clinical application of preparations in ethnic medicine hospitals, and carry out research and development of new ethnic medicine with clear mechanism, high technology content and reliable curative effect.

Build a characteristic industrial cluster of Sanqi, and build Sanqi into the first brand of traditional Chinese medicine in China. We will build a Sanqi industrial innovation consortium with enterprises as the main body, and gather superior resources inside and outside the province to carry out key technology research and transformation and application of achievements. Develop innovative drugs for prevention, treatment and rehabilitation of cardiovascular and cerebrovascular diseases; Focusing on the large varieties and exclusive varieties of traditional Chinese medicine (ethnic medicine) such as Sanqi series and Dengzhanhua series, we will increase the re-evaluation after listing and the secondary development of "new use of old drugs", and carry out research on the combination of traditional Chinese and western medicine such as "Xuesaitong+aspirin"; Strengthen the biosynthesis and application of panax notoginseng saponins, scutellarin, Paris polyphylla saponins and other extracts; Carry out research on the processing technology and technology of traditional Chinese medicines such as Panax Notoginseng while fresh, and formulate standards for new-type decoction pieces such as formula granules and powder decoction pieces of characteristic varieties such as Panax Notoginseng and Gastrodia elata which meet the standards of People’s Republic of China (PRC) Pharmacopoeia; To study and formulate EU Pharmacopoeia standards for Sanqi formula granules, panax pseudo-ginseng and other products, so as to enhance the international popularity and influence of Sanqi.

Regional cooperation in the research and development of traditional Chinese medicine (ethnic medicine) should be carried out for South Asia and Southeast Asia, international multi-center clinical trials and international registration of traditional Chinese medicine preparations with good clinical effect and clear mechanism of action should be carried out, and a modern standard production system and quality evaluation system of traditional Chinese medicine should be constructed according to international standards.

(3) Health products based on natural extracts.

Continue to strengthen the research on the material basis of effective active ingredients of animals and plants, increase the development and application of extracts, strengthen the development of high-quality health products, and cultivate brand products with market competitiveness and scale effect.

Focus on Kunming, Yuxi, Chuxiong, Pu ‘er, Xishuangbanna, Lijiang, Wenshan and other cities to build health product research and development and production bases, and develop high value-added health products. Focus on health care products and daily chemical products such as Sanqi series, Dendrobium series and microalgae series, and build a number of brand products with sales income exceeding 1 billion yuan. Introduce well-known enterprises at home and abroad, cultivate some leading enterprises, and promote Yunnan’s health products to South Asia and Southeast Asia.

Construction of Yunnan laboratory for extracting characteristic plants. Focusing on plant extraction and scientific and technological innovation in the whole industrial chain of health products, we will systematically carry out basic research, product development and achievement transformation, and build a platform for functional evaluation and inspection of health foods and cosmetics. Using modern biotechnology, we will strengthen the research on the efficacy and application of animal and plant-derived ingredients, cultivate and expand a number of intensive processing backbone enterprises in the main raw material producing areas in view of the needs of food, medicine, health care products, daily chemical products, feed products and other related industries, and promote the extraction and processing of characteristic Chinese herbal medicines such as Panax notoginseng, Periplaneta americana and leech, as well as the raw materials of characteristic health products such as stevia rebaudiana, eucalyptus globulus, marigold, maca, rose, microalgae and aloe, and research and development. Improve the extraction and separation technology and quality level of panax notoginseng saponins, breviscapine, tea polyphenols, coenzyme Q10, paclitaxel, borneol and other extract products, as well as eucalyptus oil, citronella oil, rose oil, rosemary and other essence and fragrance products. Taking notoginseng, gastrodia elata, Dendrobium nobile, Polygonatum sibiricum, Amomum villosum and other medicinal and edible Chinese herbal medicines as raw materials, and special biological resources such as microalgae, Moringa oleifera, walnuts and flowers as raw materials, we have researched and developed various health products such as medicated diet, medicated wine, medicated tea and drinks, as well as a series of health foods, aromatic products and daily necessities with the functions of resisting oxidation, losing weight, enhancing immunity, relieving anxiety, relieving depression, assisting in improving memory and caring skin. Focus on developing and producing a batch of formula foods with strong pertinence and high patient acceptance, which are suitable for surgery, nephrology, oncology, pediatrics and geriatric rehabilitation.

Improve the development level of Panax notoginseng extract. In-depth study of extracts from different parts such as flowers, stems, leaves, roots, etc., and development of Sanqi series health food, special diet products, oral care, medical beauty skin care and other daily necessities in different dosage forms such as tablets, capsules and oral preparations, enriching product structure and expanding application fields; Improve the extraction technology and product quality level of panax notoginseng saponins, polysaccharides and panax notoginseng elements; Study and formulate international standards for the extraction of characteristic raw materials such as Panax notoginseng, and accelerate the internationalization of Panax notoginseng.

2. Rapid development areas

(1) Chemical drugs

Further improve the industrial chain, improve the research and development capabilities of original drugs and generic drugs, and improve the research and development level of high-end preparations.

Focus on Kunming, Chuxiong and other cities to build R&D and production bases for chemical drugs and chemical raw materials, and carry out R&D and industrialization of innovative drugs, improved new drugs, generic drugs and chemical raw materials.

Strengthen the joint development of "intermediates+APIs+chemicals". Improve the production technology of platinum anti-tumor raw materials and steroid hormone raw materials. Encourage enterprises to buy varieties with high clinical value at home and abroad and enterprises with great development potential to enter Yunnan for development. Develop chemical raw materials, auxiliary materials and packaging materials industries in areas with resources and environmental carrying capacity, and develop a number of chemical synthetic drugs with characteristics, potential and competitiveness. Strengthen exchanges and cooperation with Israel, India and other countries in the research and development of generic drugs, and explore the construction of an international cooperation base for the research and development of generic drugs.

Guide key enterprises and scientific research institutions to focus on the development of innovative drugs for major diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, diabetes, mental diseases, viral infections, etc., especially chemical innovative drugs and improved new drugs with new targets and new mechanisms of action. Carry out research and development of high-end preparations, develop new dosage forms with good clinical substitution for varieties and dosage forms that are clinically necessary and have great side effects, and promote the research and development of sustained and controlled release, targeted, transdermal, mucosal and carrier drug delivery systems. Develop Yunnan plant resources, discover and develop new natural chemical drugs. To carry out the imitation of drugs needed for the treatment of major infectious diseases and rare diseases, drugs needed for the disposal of public health emergencies, drugs used by children, and original drugs whose patents are about to expire. Carry out research and development and green production technology innovation in the fields of chemical raw materials and pharmaceutical intermediates; Carry out the construction of the process technology system for the biosynthesis of important pharmaceutical monomer compounds such as panax notoginseng saponins and breviscapine.

(2) Medical devices

Give full play to the advantages of China (Yunnan) Pilot Free Trade Zone (hereinafter referred to as FTZ) and Border Economic Cooperation Zone, speed up the construction of medical device production and trade system for South Asia and Southeast Asia, develop high-tech and high value-added products, and establish an effective linkage mechanism between medical institutions and medical device industry.

We will build medical device industrial parks in Central Yunnan New District, Qujing, Yuxi, Free Trade Zone and Border Economic Cooperation Zone, build medical device R&D and production, inspection and testing, and trade distribution bases for South Asia and Southeast Asia markets, and build the most complete medical device industrial park in Southwest China.

In view of the market demand in South Asia and Southeast Asia, we will introduce domestic and foreign leading or advantageous enterprises in high-end medical devices and biomaterials to build medical device production bases and supporting industrial chains, cultivate high-end medical device enterprises, and promote the development of upstream and downstream industries of medical devices. Support the construction of a production base that meets the quality management standards for medical device production, build a public R&D and production platform for medical devices, build a high-grade medical device life-cycle detection technology service platform based on units with good foundation, and attract enterprises, research institutions, talent teams and technological achievements to Yunnan to carry out the transformation and industrialization of achievements. We will build a number of leading enterprises in the production of in vitro diagnostic reagents, dentures and disposable infusion devices, and promote the development of industries such as medical devices, new biomaterials, high-end pharmaceutical packaging materials and high-quality pharmaceutical excipients.

Develop technologies and products such as gene detection, biological detection chip and in vitro immunodiagnosis, and develop in vitro diagnostic equipment and reagents such as major emerging infectious diseases and tumor diseases; Accelerate the research and development of new biomaterials, and carry out research and development of new biomaterials such as biomedical materials, tissue engineering materials, bio-based materials and medical and health materials; Carry out research and development and production of high-end consumables such as orthopedic instruments, and build a production base of high-end orthopedic consumables in southwest China; Carry out research and development of TCM diagnosis and treatment instruments and equipment, rehabilitation instruments and equipment, and sports therapy equipment with ethnic characteristics; Carry out the development and industrialization of "big data+artificial intelligence+medical care" instruments and equipment, and develop digital and multifunctional mobile monitoring equipment and wearable products, rehabilitation AIDS and optometry-related products.

(3) Veterinary drugs

Further guide enterprises and scientific research institutions, strengthen investment in veterinary drug research and development, enhance the research and development ability of veterinary drugs, and give full play to the advantages of resources to develop innovative products of veterinary drugs.

Strengthen the cooperation between animal medicine enterprises and scientific research institutions inside and outside the province, and develop or introduce a new generation of animal vaccines and innovative products for veterinary medicine. Improve the quality and production capacity of a number of veterinary drugs, such as bovine O-type and A-type foot-and-mouth disease inactivated vaccine, pig O-type foot-and-mouth disease inactivated vaccine, pig double O-type foot-and-mouth disease inactivated vaccine, hog cholera live vaccine (subculture cell source), piglet paratyphoid, Newcastle disease and so on.

Focus on Kunming, Baoshan, Dali and other cities with veterinary drug industry base to actively develop veterinary drug industry. Increase the research and development of livestock and poultry disease prevention vaccines and pet vaccine products such as cattle, sheep, pigs and chickens; Develop a batch of veterinary traditional Chinese medicine preparations with traditional Chinese medicine as raw materials, which can replace antibiotics, carry out veterinary drug imitation research, develop feed drug additives, improve the self-sufficiency rate of veterinary drug production, and actively expand the market in South Asia and Southeast Asia.

(2) To improve quality and accelerate the construction of high-quality raw material bases for Chinese herbal medicines.

Highlight the construction of standardized planting (breeding) bases for Chinese medicinal materials, adhere to the principle of quality first, control the planting scale, innovate the planting mode, promote the original habitat planting, improve the quality of medicinal materials, and scientifically develop large varieties of raw materials such as Panax notoginseng, Erigeron breviscapus, Paris polyphylla, Gastrodia elata and Dendrobium. At the same time, give play to ecological advantages, actively introduce domestic and foreign high value-added medicinal varieties into Yunnan to build a high-quality raw material planting and processing base. Make good use of domestic and foreign resources and markets to build Yunnan into a national raw material base for high-quality natural medicines and health products.

1. Breeding excellent provenances and developing the fine variety industry of Chinese herbal medicines.

In order to promote the sustainable development of Chinese herbal medicine resources, the collection and evaluation of germplasm resources, screening of high-quality provenances, breeding of new varieties and breeding of improved varieties will be carried out around the backbone medicinal materials and rare and endangered Chinese herbal medicines, and the industry of improved varieties of Chinese herbal medicines will be developed. In view of the problems such as source degradation, we will strengthen the domestication and planting of Chinese herbal medicines and the breeding of improved varieties. Strengthen the investigation, collection, identification, preservation and artificial domestication and cultivation techniques of important rare and precious wild raw material germplasm resources such as Fritillaria cirrhosa, Euphorbia Humifusa, Rhizoma Curculiginis, Rhubarb and Dragon’s Blood, and protect the germplasm and genetic resources. In Wenshan, Zhaotong, Chuxiong, Dali, Lijiang, Pu ‘er, Baoshan and other authentic Chinese herbal medicine producing areas and suitable planting (breeding) areas, 50 breeding bases of authentic superior Chinese herbal medicines, 100 guaranteed nursery bases of Chinese herbal medicines and 100 standardized planting (breeding) bases will be upgraded, and a number of Chinese herbal medicine seed and seedling enterprises will be built, with emphasis on cultivating more than 10 high-quality seed and seedling management companies. Relying on the National Nature Reserve, conservation zone, a Chinese herbal medicine, will be built, and more than two protected areas for endangered and rare wild medicinal plants and animals will be planned, and more than 10 wild breeding bases for endangered and rare genuine medicinal materials from Yunnan will be built to provide support for the rapid development of raw materials industry for health products.

2. Strengthen the construction of high-quality raw material bases and build high-quality Chinese herbal medicine planting areas.

Build the "first workshop" of biomedical industry with the concept of green development. According to GAP standards, develop rural areas to revitalize the "one county, one industry" Chinese herbal medicine planting (breeding) industry. Innovate the planting (breeding) mode and vigorously develop "green planting", "ecological planting", "under forest planting" and "imitation of original habitat planting" of Chinese herbal medicines. Encourage domestic and foreign enterprises to build a "pharmaceutical park" in suitable areas of Yunnan, and accelerate the formation of a situation in which leading enterprises lead, bases are standardized and the province develops in an orderly manner. Cultivate a number of well-known enterprises and high-quality raw material varieties, and build a standard library of reference materials for Chinese herbal medicine varieties. Cooperate with neighboring countries to protect and organize traditional medicinal resources in South Asia and Southeast Asia, popularize planting techniques and carry out overseas planting. Strengthen the research and development and application of advanced equipment for planting Chinese herbal medicines, and improve the modernization level of planting (breeding) Chinese herbal medicines. Cultivate original bulk and regional comprehensive primary processing bases of Chinese herbal medicines, and lay out and build regional inspection and testing platforms.

Give full play to the advantages of Yunnan’s ecological environment, national culture and tourism industry, and promote the construction of a number of Chinese herbal medicine health industrial parks (manors) including standardized cultivation (breeding), food culture, health experience, leisure and health preservation, and popular science propaganda, with emphasis on building more than 10 well-known manors.

3. Accelerate the improvement and efficiency of "the hometown of Yunnan medicine" and build the brand of "Yunnan medicine"

Relying on the "Hometown of Yunyao", we will promote the construction of more than 60 standardized, large-scale and standardized planting (breeding) areas of high-quality Chinese herbal medicines, improve the standards of authentic Chinese herbal medicines, study and formulate a number of domestic and international standards for raw materials of health products, expand the scale of green planting and ecological planting of Chinese herbal medicines, standardize the whole process management of raw material planting (breeding), and build a quality monitoring network and traceability system covering the main producing areas of Chinese herbal medicines in the province. Build a green production technology promotion system, a production processing technology system, a quality evaluation system and a traceability system of the whole industry chain, and build a "Top Ten Yunyao" brand. We will carry out basic research on pharmacology, medicalization, efficacy and safety evaluation of Chinese herbal medicines, and develop a number of new food raw materials.

Build Sanqi into a national demonstration variety of Chinese herbal medicine intelligent agriculture. Improve the technology and level of green planting, undergrowth planting and original habitat planting of Panax notoginseng, and improve the supply capacity of high-quality and high-end products. Around the breeding, planting, processing, warehousing and other links of improved varieties of Panax notoginseng, we will build a comprehensive and domestic leading big data platform for intelligent agriculture of Panax notoginseng, and build a digital management and service system for seed and seedling quality evaluation, monitoring and early warning of pests and diseases, intelligent diagnosis, processing of origin, warehousing and logistics, quality inspection, product traceability and so on.

(three) to expand the market and accelerate the improvement of the business system of biomedical products.

Based in Yunnan, facing the whole country, South Asia, Southeast Asia and the Indian Ocean Rim, with the help of internet plus, big data, cloud computing and other modern technical means, we will give full play to the role of free trade zones and border economic cooperation zones, vigorously carry out internal and external cooperation, and build a business system for biomedical products with the focus on market system construction, enterprise management informationization and international business development.

1. Build a regional circulation system

Focusing on free trade zones and border ports, we will lay out and build a number of modern warehousing and logistics centers for biomedical products in all provinces, cities and key counties, cities, districts and border port cities such as Hekou and Ruili, build regional pharmaceutical wholesale and distribution centers, build cold chain logistics, and improve the supply guarantee system for pharmaceutical and health products in Yunnan. High-level construction of Yunnan Chinese herbal medicine trading center, enlarge and strengthen Wenshan Sanqi, Zhaotong Tianma and other regional characteristic Chinese herbal medicine markets, build a futures market for bulk medicinal materials and scarce medicinal materials, and cultivate a regional distributed trading market for fresh medicinal materials. Strengthen the supervision of Chinese herbal medicine market, standardize the access management of Chinese herbal medicine market, and establish a quality inspection, public warehousing and quality traceability system.

2. Promote the development of new logistics formats

Promote the "internet plus" business model, encourage drug circulation enterprises to use the Internet and Internet of Things technology, introduce third-party service organizations such as insurance and logistics, provide extended services such as online pharmacies and drug distribution, and build an information management system covering the whole province’s business circulation. Taking the Chamber of Commerce as the main body, we will jointly build the "Yunyao Information Network" and "Yunyao Database" to build the Yunnan pharmaceutical e-commerce trading platform. Develop the platform economy of "internet plus Traditional Chinese Medicine+Traditional Chinese Medicine+Health Service" and build a new format and new model economy of Chinese medicine industry.

3. Broaden the market channels of Yunyao.

Strengthen cooperation in commercial production, encourage commercial circulation enterprises inside and outside the province to sell Yunnan products, guide commercial circulation enterprises to build production and marketing alliances with raw material planting enterprises and pharmaceutical and health care products production enterprises, and provide market information and sales channels for production enterprises. Develop a number of specialized institutions that exchange and cooperate with domestic and foreign countries, and hold various seminars, exchanges and exhibitions. Encourage business circulation enterprises in the province to become bigger and stronger, and lead production enterprises, especially small and medium-sized enterprises, to expand domestic and foreign markets.

Fourth, the main measures

(1) Vigorously implement accurate investment promotion.

In-depth implementation of the "multiplication" plan of market players, focusing on biotechnology drugs, modern Chinese medicine, chemical pharmaceuticals, health products and other fields, aiming at the top 500 international companies, the top 100 biomedical companies and leading enterprises in the industry, and carrying out accurate investment promotion. Implement the drug marketing license holder system, and introduce innovative achievements holders such as biotechnology drugs, innovative Chinese medicines and chemical medicines to Yunnan to carry out achievements transformation and industrialization. Introduce and develop serum-free cell culture medium, affinity filler medium, ultrafiltration membrane, disposable reaction bag and other upstream and downstream supporting enterprises of biological products represented by vaccines to enter Yunnan for development. Introduce Chinese herbal pieces and health products processing enterprises represented by formula granules into Yunnan to build a raw material base, research and development production base and extend the industrial chain of Chinese herbal medicines. Implement the medical device holder system, give full play to the advantages of free trade zone and border economic cooperation zone, introduce medical device R&D and production enterprises to Yunnan, and build a medical device production and circulation base for South Asia and Southeast Asia. Introduce chemical raw material medicine enterprises into Yunnan for development in areas with resources and environmental carrying capacity. In combination with the introduction of science and technology into Yunnan, we will actively promote the "four landings" of talent teams, scientific and technological enterprises, scientific and technological achievements and innovation platforms, and strengthen the introduction of CRO (contract research and development institutions) and CMO (commissioned production institutions).

(2) Accelerate major projects.

Implement special projects for the development of biomedical industry, organize and implement a number of key projects to support and lead the development of biomedical industry. Relying on leading enterprises and R&D institutions with strong R&D capabilities, we will organize and plan a number of major projects combining "Industry-University-Research" for the development needs of key areas of biomedicine. With the goal of leading enterprises and key brand products becoming bigger and stronger, we will implement a number of quality improvement and efficiency improvement projects through digital and intelligent technological transformation and secondary development. With the goal of building industrial clusters, support key cities, key parks and key enterprises to plan and implement a number of key projects. Encourage the park to plan a number of preliminary projects and implement a number of key projects around infrastructure construction, key industrial bases construction and major scientific research platforms construction, and strengthen tracking management and service guarantee.

(C) focus on cultivating leading enterprises

Implement the cultivation plan of leading enterprises, and comprehensively improve the comprehensive competitiveness of pharmaceutical enterprises. In accordance with the principle of "one thing, one discussion, one enterprise, one policy", we will enlarge and strengthen leading enterprises, cultivate a number of large enterprise groups with international influence, develop and expand a number of key enterprises, support the development of small and medium-sized enterprises, and form enterprise clusters. In the fields of traditional Chinese medicine, biotechnology medicine, chemical medicine and health products, select a group of enterprises with good growth to focus on cultivation. Support enterprises to build raw material bases and production bases around the industrial chain, and improve the level of automation, intelligence and informatization of enterprises. Carry out the listing cultivation of biomedical enterprises, and continue to promote the listing progress of biomedical "golden seed" enterprises. Support enterprises to take capital, technology, brand as the link, through mergers and acquisitions, agreement transfer, joint restructuring, holding shares and other ways to carry out mergers and acquisitions, improve industrial concentration.

(4) Continuously improve the innovation capability.

Focusing on the fields of vaccines, antibody drugs, cell products, modern Chinese medicine, formula granules, chemical drugs, health products, extracts, etc., we will upgrade and build a number of industrial public service platforms and specialized research and development platforms, form a perfect biomedical research and development and technical service chain, and continuously improve the ability of biomedical innovation. Keep a close eye on the commanding heights of industry technology, increase investment in applied basic research, and reserve a number of advanced and applicable technologies and achievements; Adopt the innovative project organization mode of "unveiling the list", aim at the major needs of the industry, break through key technologies, formulate new standards, develop new products and upgrade new processes. With enterprises as the main body, we will build a number of R&D and service platforms such as key laboratories, technology innovation centers, engineering research centers, enterprise technology centers and industrial technology innovation platforms in conjunction with well-known expert teams and scientific research institutions at home and abroad. Promote the construction of the State Key Laboratory of Biomedicine for Non-human Primates, accelerate the construction of Yunnan Laboratory for Extraction of Characteristic Plants, build a new vaccine technology innovation system, and improve the research platforms such as natural drug screening, research on patent medicine, drug safety evaluation (GLP), drug pilot test, drug clinical evaluation platform (GCP) and bioequivalence test. Construction of provincial clinical medical research centers and a number of national clinical medical research sub-centers. Cultivate and introduce several CRO institutions. Promote and build a platform for big data and digital applications around the biomedical industry chain.

(5) Building professional parks with high quality.

With Kunming as the center and Yuxi, Chuxiong, Wenshan, Qujing, Baoshan, Honghe and other cities as the focus, a number of biomedical industry specialized parks covering the whole province will be built. Focus on promoting Kunming National Bio-industrial Base, Yunnan Central Traditional Chinese Medicine Natural Medicine Economic Circle, Yunnan Central Medical Device Industrial Park, Kunming and Yuxi Bio-vaccine R&D and production bases, International Medical Health City, Chuxiong Traditional Chinese Medicine Formula Granule Industrial Base, Wenshan High-tech Industrial Development Zone, Tengyao Industrial Park, Pu ‘er Biomedical Industrial Park, Honghe Biomedical Industrial Cluster, Qujing Malong Medical Device Emergency Industrial Park and other specialized parks and clusters. Based on the evaluation of the carrying capacity of resources and environment and the suitability of land and space development, chemical raw material medicine parks will be developed in Kunming, Chuxiong and other areas that meet the relevant policy requirements of chemical parks. Promote the gathering of projects, funds, talents and other elements in the park, strengthen the construction of public R&D and service platform, industrial incubation, infrastructure, industrial facilities and human resources conditions in the park, and form a regional specialized park integrating research and development, enterprise incubation, manufacturing and logistics distribution. Strengthen cooperation with biomedical industrial parks in Beijing-Tianjin-Hebei, Yangtze River Delta, Pearl River Delta and other regions, attract large domestic and foreign pharmaceutical enterprises, scientific research institutions and teams, CRO institutions and CMO institutions to settle in the parks, promote industrial agglomeration development, vigorously promote the construction of Kunming Great Health Industry Demonstration Zone, and build Kunming and Yuxi into important bases and agglomeration areas for modern biomedical production and research, and Chuxiong, Wenshan and other cities into important bases for modern Chinese medicine industry.

(6) Accelerate the training and introduction of talent teams

Adhere to the problem orientation, deploy the talent chain around the industrial chain and innovation chain, promote all kinds of talent training and introduction programs to the biomedical industry, further strengthen the training and introduction of high-level talents, and introduce high-end management talents, leading scientific research talents, high-level technical talents and innovative teams through multiple channels. Innovate training methods, train all kinds of talents, expand the enrollment scale of biomedical related majors in colleges and universities, and establish specialized talent training bases relying on qualified colleges and universities. Encourage social capital to set up vocational colleges and training institutions, promote school-enterprise cooperation, jointly cultivate and improve the quality of employees, and focus on cultivating a number of scientific and technological research and development talents, enterprise management talents, marketing talents, licensed pharmacists, quality management, testing and consulting service talents. Encourage the park to set up special funds for talents to provide more powerful talent support for the high-quality development of biomedical industry.

(7) Focus on building the brand of Yunyao.

Focus on the superior products such as vaccine series, Sanqi series and Dengzhanhua series, and build the brand of "Yunyao". To build a biological vaccine brand, we should build a specialized vaccine industry park, build a vaccine research and development system, develop innovative vaccine products, and promote the international development of vaccines. Extend the industrial chain of large varieties of Chinese herbal medicines such as Panax notoginseng, Erigeron breviscapus, Paris polyphylla, Dendrobium, Gastrodia elata, cultivate a number of large varieties of Chinese herbal medicines, and create geographical indication protection varieties. Develop ethnic resources of traditional Chinese medicine, develop and expand a number of dual-purpose varieties of traditional Chinese medicine, and promote the formation of a number of brand products such as Chinese herbal pieces, extracts, health foods and functional cosmetics. Implement the promotion action of famous Yunnan medicine products, give play to the leading role of the propaganda department, and form a publicity system with the participation of the government, enterprises and social organizations. Encourage enterprises to carry out various forms of publicity and promotion activities to publicize the advantages, characteristics, achievements, enterprises, brands, products and people of Yunnan’s development of biomedical industry. Build a brand display platform through various trade fairs such as South Expo and Drug Fair.

V. Guarantee conditions

(A) to strengthen organizational leadership

Improve the bio-pharmaceutical industry promotion mechanism, compact work responsibilities, hold regular meetings, analyze industrial development, study industrial policies, deploy promotion work, coordinate and solve key problems in the development of key enterprises and major projects, and promote vertical linkage at the provincial, prefecture and county levels. Further improve the horizontal linkage mechanism of provincial departments, enhance the joint efforts of all departments to promote the development of biomedical industry, and jointly create a good environment to promote the high-quality development of biomedical industry in Yunnan. An expert advisory committee on biomedical industry composed of senior experts in relevant fields inside and outside the province was established to provide strategic advice on the frontier situation, industrial analysis, innovation ability, regional layout, key investment promotion and policy design of Yunnan biomedical industry.

(2) Increase policy support.

Focusing on the research and innovation of new products, achievements transformation, market development and innovative service system construction in the fields of biotechnology drugs, modern Chinese medicine, chemical drugs, medical devices and health products, we will coordinate financial funds, increase investment and refine specific measures to support the innovation and development of biomedical industry. To obtain the national major new drug creation science and technology projects, the national key research and development plan related key projects, according to the law and regulations to give supporting support. Support for key core technology research and key new product development, comprehensive use of open competition, publicity system, horse racing system, directional selection and other ways to organize major innovation projects. Study and formulate policies and measures to support the development of biomedical industry in the free trade zone, and help Yunnan biomedical industry to go out and introduce. Incorporate key projects and major projects involving industrial development into relevant national development plans and strive for national policy support. Actively strive for the inclusion of superior and characteristic drugs in the national basic medical insurance drug list and the national basic drug list. Encourage all localities to adopt the form of "government subsidies, enterprises making profits and people buying" to promote the project of biological vaccines benefiting the people. Deepen the "streamline administration, delegate power, strengthen regulation and improve services" reform and promote the development of industrial agglomeration.

(3) Overall factor guarantee

Through scientific planning, revitalizing stocks, introducing increments and other ways, we will further expand the development space of biomedical industry, and encourage industrial parks to build standardized factories to meet the needs of biomedical R&D and production enterprises on the basis of meeting the requirements of land and space planning and environmental assessment at all levels. Overall balance of land use, electricity consumption, water consumption, sewage and other indicators, scientific planning and layout of biopharmaceutical and innovative drug production bases. Encourage the park in accordance with the principle of intensive land use, overall planning for the protection of the park urgently needed talent introduction, employment units or park employees accommodation construction land. Focus on advantageous fields and varieties, establish key enterprises and project libraries, give preferential policies to key projects, and streamline examination and approval procedures according to laws and regulations.

(D) Expand financing channels

Give full play to the role of provincial financial control group industrial investment fund, and guide key cities and parks to set up biomedical industry investment funds. Strengthen cooperation with various investment companies, banks and other financial institutions, and adopt various ways and mechanisms such as listing financing, equity investment, credit guarantee, risk compensation, bond financing and asset management to promote base construction, product development, achievement transformation and industrialization, enterprise cultivation, brand building and market expansion.

(5) Strengthening digital empowerment

Promote the digitalization of resources, digital industrialization and industrial digitalization in the biomedical field. Apply modern information technologies such as blockchain, big data and artificial intelligence to upgrade the construction of Yunnan biomedical industry big data center, and further improve the production, supply and marketing network of biomedical enterprises, Chinese herbal medicine bases and circulation enterprises covering the whole province. Promote the construction of Yunnan biological resources digital integration center to realize the sharing, trading and calculation of biological resources scientific data. Give play to the role of industrial big data platform, promote data sharing in R&D, production, approval, sales and use, and break down departmental data barriers.

(6) Pay attention to safety and security.

Strengthen the construction of biosafety risk prevention and control and governance system, strengthen the supervision and management of high-risk and medium-risk biotechnology research and development activities, and take effective countermeasures. Give full play to the role of Yunnan Science and Technology Ethics Committee, strengthen overall planning and guidance, strengthen scientific research ethics supervision, standardize all kinds of scientific research activities, strengthen safety training for managers and professional and technical personnel, and ensure the safe and healthy development of biotechnology. We will comprehensively promote the construction of drug safety regulations and standards system, highlight the improvement of supervision efficiency, enhance the ability of drug monitoring and evaluation, audit and inspection, inspection and testing, and intelligent supervision, and realize the mutual promotion of safety supervision and industrial development. Combine the construction of the vanguard of ecological civilization construction, implement the concept of green development, strengthen environmental protection during the development and application of biotechnology products, and ensure ecological security.

(7) Strengthen evaluation and supervision.

Establish a dynamic evaluation mechanism for the implementation of the plan, formulate a task list every year, and regularly supervise the implementation of the plan by the relevant departments of the state, city and province. We will build a supervision and service mechanism for the operation of key enterprises and the construction of major projects, strengthen the operation monitoring of key enterprises and the scheduling, tracking and service of key projects, and promote the early commencement, completion and commissioning of projects.

Attachment: 1. Atlas of Yunnan Biomedical Industry Chain

2. Regional distribution map of "hometown of Yunyao"

3 main indicators, main tasks and key work responsibilities.

Annex 1

Annex 2

Annex 3

　　"Dad, are you ready?" At the beginning of June, a series of copywriting appeared in an advertisement of a medical beauty client to warm up the newly launched "Double Eyelid Festival". This advertisement, which blew up the elevator, also caused widespread controversy because of the encouragement to young medical beauty practitioners implied by the word "Dad".

　　According to the analysis of the 2018 medical beauty industry white paper released by a medical beauty service platform, among every 100 medical beauty consumers in China, there are 19 "post-00", and the momentum of starting medical beauty consumption after 00 is stronger than that after 90. In 2019, the proportion of medical and beauty consumers under the age of 19 in China has reached 15.48%.

　　There are indications that the plastic surgery population is gradually becoming younger. Then, why did "after 00" choose cosmetic surgery early? What is the significance of plastic surgery for them? Is it necessary to have plastic surgery at a young age? Qianjiang evening news reporter conducted an investigation on this.

　　In plastic surgery, minors often appear accompanied by their parents.

　　Engaged in plastic surgery for four years, every winter and summer vacation, Liu Jun, a plastic surgeon in a 3A hospital in Hangzhou, will witness the peak of student gathering. "Almost every month, 60 or 70 students come for cosmetic surgery, accounting for 30%~40%."

　　"Most of them are high school graduates. Because they are about to enter the university, they hope to meet a new life and a new social circle with a better self." In recent years, the demand for medical beauty of high school graduates has been increasing year by year. Liu Jun understands their mentality, but from time to time he will meet several young medical beauticians who are at a loss.

　　"Campus Beauty" Trouble: Am I not very pretty?

　　The girl opposite talked about her various facial defects without thinking. But Liu Jun clearly saw that her face was white and beautiful, her skin was transparent and full, and her facial features were correct. He silently scored 95 points for the girl’s face value.

　　The girl’s name is Fangfang, 15 years old, and she is in Grade Three. She looks in the mirror frequently every day, makes "ugly" comments on herself distorted in her mind countless times, and consults medical beauty everywhere at any cost.

　　Finally, one summer, Fangfang, accompanied by her mother, sat in front of Liu Jun.

　　Liu Jun clearly saw that the girl’s eyes revealed a desire for change — — "My palate is leaning forward. Can I push it back?"

　　After entering the door, Fangfang’s mother just stood by without saying a word, smiling helplessly at Liu Jun.

　　"You are beautiful, there is no need to fix it." Liu Jun interrupted Fangfang’s words and directly denied her biased cognition of herself.

　　"You see, that’s what doctors say." At this time, the mother on the side spoke the first sentence, "I have been persuading for a long time before, but my daughter just doesn’t believe it."

　　In fact, because of her outstanding appearance, Fangfang, the "school flower", has always attracted much attention. But since entering junior high school, I heard someone say that another girl in other classes is more beautiful than herself. Fangfang has been dissatisfied with her appearance since then and started all kinds of strange behaviors.

　　"She is very demanding about her appearance and will constantly exaggerate her shortcomings. It is likely that there is a problem at the psychological level." After rejecting Fangfang’s plastic surgery idea, Liu Jun also made suggestions to the girl’s mother — — Pay attention to children’s psychological state.

　　A boy who visits the plastic surgery department once every three months

　　In the plastic surgery department where Liu Jun is located, Kobayashi, a boy under the age of 20, is also a frequent visitor. "Almost every quarter, he will come once, and the needs are different every time. In addition to me, many doctors also took care of him. "

　　Kobayashi is well-behaved, but he has been particularly concerned about his appearance since high school, and he can constantly find new defects. When he was still in high school, Kobayashi had a mandibular osteotomy in another hospital.

　　"Because of grinding, he has produced new dissatisfaction. Come to me for consultation six months after the operation. " Liu Jun said, "The boy’s mother also took great pains to greet me in advance alone, hoping that I would persuade her son."

　　Liu Jun successfully persuaded Xiaolin to go home, but half a year later, Xiaolin’s mother found the door again. "My son has been good for a while, but now he is entangled again."

　　Although Liu Jun repeatedly persuaded him not to have plastic surgery, Kobayashi always insisted on changing it, but he couldn’t tell the purpose and reason. "Because he paid too much attention to his appearance, he couldn’t concentrate on his studies. He only read until he graduated from high school." Liu Jun guessed that he might be psychologically hit by reasons such as lovelorn love. The best solution is not to find a plastic surgeon like Liu Jun..

　　"Go to the mental health department." In the face of young medical beauticians, Liu Jun often makes such suggestions.

　　Continue to write your own aesthetic mother on your children’s faces.

　　For cosmetic surgery, sometimes the young "post-00" will disagree with their families. "Some children really want to do it, and parents feel that it is unnecessary; There are also some children who have not yet formed aesthetics, but parents impose their own ideas on their children. "

　　"The child is still young, why do you want to cut her double eyelids?" Engaged in medical beauty for 28 years, Zhang Jufang, director of the medical beauty department of Hangzhou First People’s Hospital affiliated to Zhejiang University, met such a small patient for the first time — — Xiao Min, a 13-year-old junior high school girl.

　　"I think her eyes are not good-looking, and girls should have a pair of beautiful big eyes." Xiao Min’s mother said.

　　Zhang Jufang looked at Mandy sitting next to her. She listened to the conversation between adults with a puzzled expression on her face. Xiaomin knows nothing about plastic surgery. She only knows, "Mom asked me to do it, and I will do it."

　　After hearing Xiaomin’s answer, Zhang Jufang refused the operation. "The child didn’t ask for it herself. This operation is meaningless to her. Parents can’t make decisions for their children with their own aesthetics. " She told Xiaomin’s mother that she should decide whether to make facial adjustment after Xiaomin became an adult and formed her own aesthetic view.

　　Liu Jun also met a similar mother and daughter.

　　"As soon as I entered the door, the girl’s mother eagerly told me that her daughter’s eyes were ugly and her nose was ugly … … It doesn’t look good anywhere. "

　　Liu Jun remembers that it was an ordinary-looking high school girl who did have some defects, but the girl herself didn’t care about her appearance. "This mother’s mentality is a bit abnormal and she insists on plastic surgery for her children."

　　Plastic surgeons suggest:

　　Minors should not choose medical beauty.

　　Children’s psychology needs more attention.

　　"One of the most important tasks of plastic surgery clinics is to screen people and understand their plastic surgery purposes clearly." Liu Jun said with emotion, "Some children, we look normal, but they may be distorted in his eyes. In fact, this is a mental disorder and a kind of psychological paranoia. Plastic surgery can’t cure their mental illness. "

　　For young medical beauticians, double eyelid cutting and rhinoplasty are the most popular cosmetic items. According to the data released by a medical beauty service platform, "post-00" has quickly taken over from "post-90" and become a big consumer of medical beauty in double eyelid surgery.

　　Zhang Jufang also disagreed with the "66 Double Eyelid Festival" launched for the medical beauty service platform. "This is a marketing tool that sells double eyelids as products." Zhang Jufang said that double eyelids are an operation, not an assembly line product, and cannot be mass-produced. "It is not advisable to set a double eyelid festival, carry out large-scale promotion and encourage everyone to do double eyelids."

　　"Choosing medical beauty for younger people, from a clinical point of view, we are mainly based on two considerations." Zhang Jufang said, "Some children have congenital defects, such as cleft lip and palate. Performing cosmetic surgery for children can help him build confidence from an early age; Others are to make up for children’s psychological trauma and eliminate inferiority complex. For example, some girls have black hair moles on their faces and are teased by classmates. "

　　For young medical beauty practitioners, Liu Jun suggested, "We should wait until adulthood and establish a mature aesthetic view before considering this matter."

　　Zhang Jufang also believes that "minors should not choose medical beauty, and parents can’t ask their children for plastic surgery for their own needs. College students need to establish correct values and aesthetics, and they can pursue beauty, but not blindly. If you really want plastic surgery, you should also go to a regular hospital or medical beauty institution to communicate directly with doctors and listen to professional advice. "

　　(Except for Zhang Jufang, the characters in the text are all pseudonyms.)

　　　　　　　　 Qianjiang evening news reporter Rong Zhang Chen Xi

　　At the moment when the ambulance siren sounded, in addition to the patients and their families waiting anxiously, there were also emergency medical staff who were eager to get to the scene. In the face of patients seeking help, ambulance drivers play a vital role in fighting for rescue time. In recent days, drivers in the emergency department of Jinshui District General Hospital in Zhengzhou City have become "on fire". In order to shorten the visiting time, more than a dozen drivers spent nearly half a year in their spare time to draw a visiting map covering 1,056 residential buildings in 52 communities. A few days ago, Beijing Youth Daily reporter learned from Director Zhao of the emergency department of Jinshui District General Hospital in Zhengzhou that the use of the visiting map shortened the visiting time by 5 to 10 minutes, and it will be continuously updated and improved according to the construction of residential areas within the visiting scope in the future.

　　45 hand-painted maps bring together 1056 buildings.

　　Recently, the hand-painted map of the driver’s class in the emergency department of Jinshui District General Hospital in Zhengzhou City was "on fire", especially in the emergency circle in Zhengzhou City, the provincial capital, and many people consulted "learning from the scriptures".

　　A few days ago, the reporter of Beiqing Daily contacted Director Zhao, the emergency department of the hospital. According to him, this map of visits began to be planned very early.

　　At the beginning of 2016, after Jinshui District General Hospital moved to its current new location, there were many large-scale residential areas in the core visiting area of the emergency department, and the situation of the residential areas was also complicated, many of which were special. "For example, there are 14 small courtyards irregularly distributed in a large-scale community, and each small courtyard is independent of each other and has different access controls." Director Zhao said that it is sometimes difficult for medical staff who often receive patients to find the building where the patients are located during the day, and it is even more difficult to find the road at night. "Later, we thought, can we mark the roads in each community for the convenience of all drivers?" Later, more and more communities needed to be marked, and everyone simply collected the details of more than 50 communities.

　　Shi Shuai, the driver of the emergency department, once studied painting. He was mainly responsible for sketching in the process of making the map of home visits, and the rest of the drivers were responsible for on-site exploration of the roads and entrances of the community and marking them in detail on the map.

　　It starts from Lianhuo Expressway in the north, the North Third Ring Road in the south, Jinbei Road in the west and Wenhua Road in the east. In the core visiting area of Jinshui District General Hospital in Zhengzhou City, the masters of the driver class spent half a year familiarizing themselves with the specific conditions of more than 50 residential areas, and then they were drawn on 45 hand-drawn residential area plans by Shi Shuai, the driver and first aid worker.

　　The average consultation time is shortened by 5 to 10 minutes.

　　"The traffic conditions of roads in the community, including traffic lanes and pedestrian walkways, as well as the traffic conditions of each door in the community, especially those with fire doors and fire exits, are often the most convenient first-aid passages." Shi Shuai said that in addition to marking the location number of each building in the community, it is also necessary to clearly mark the orientation position of each unit. "Especially in the case of poor sight at night, it is convenient for medical staff to quickly find the patient’s home."

　　The reporter of Beiqing Daily noticed that the contact information of the property was still left on the floor plan of many communities. Shi Shuai explained that in some high-end residential areas, it is difficult for ambulances to enter because of the separation of people and vehicles and the low underground garage door. "Everyone wrote down the switchboard of the property according to their experience. Once you receive the mission of visiting critically ill patients in the community, call the property switchboard at the first time, ask the security guard to open the ground fire door in advance, and lead the ambulance to the corresponding building to treat the patients in the most timely manner. "

　　The drawing of the home visit map directly shortens the time of receiving treatment in the emergency department. What impressed Shi Shuai was that at the end of 2017, he and his colleagues had just finished drawing the area of nearby Provence Community, and the emergency department received a call for help. Ms. Liu of Provence VI had a heart attack, and after calling 120 for help, the medical visiting team quickly determined the location according to the "visiting map". With the cooperation of the property personnel, Ms. Liu was quickly found and sent to the hospital, and finally Ms. Liu was successfully rescued.

　　"Now the 45 maps we have drawn basically cover all the reception areas of the hospital. Once we receive a phone call to confirm the location, we will find the corresponding location on the map and soon find the best way to get through. The reception time is shortened by 5 to 10 minutes on average." Shi Shuai introduced.

　　The map specially marks the location of special people.

　　In addition, Shi Shuai said that he and his colleagues also specially marked the location of special people in the community on the map. "For example, there are many elderly residents in some communities. The buildings No.19 and No.20 in a certain community are low-rent houses, and all of them live in low-income households, even the disabled and widowed elderly. In response to their help, our doctors, nurses and drivers must try their best to give special care. "

　　Master Xia worked in the emergency department of Jinshui District General Hospital for many years. Once he received a 120 call for help, he learned that an old man in his 90 s suddenly became incontinent, and his son in his 70 s took care of the old man. Because the elevator is too small, it can only be carried by people. "Master Xia picked up the old man without saying anything and sent him to the ambulance." Shi Shuai said that no matter which driver in the driver’s class encounters such a situation, he will fight for more rescue time for the patient like Master Xia.

　　Talking about the original intention of hand-painted maps, Shi Shuai said that in fact, the original intention of hand-painted maps is to compress time against time and get patients treated as soon as possible. "As long as you work in the emergency department for one day, everyone can feel that time is life."

　　"After our hand-drawn map is made, the driver class will have one copy, which greatly improves the efficiency of home visits." Director Zhao said that because of the rapid construction of Zhengzhou North District, this hand-drawn map will be further improved with the surrounding environment and the construction of residential areas.

　　Text/reporter Zhang Xiangmei

　　

　　Wei Qingyuan, an expert in Ming history. Our reporter Ma Qiang photo

　　Southern Network reported on March 21, Wei Qingyuan was born in Shunde, Guangdong Province in 1928. His major works include Yellow Book System in Ming Dynasty, Royal Guards and East and West Factories in Ming Dynasty, History of Chinese Political System, Biography of Emperor Qin Long, Zhang Juzheng and the Political Situation in the Middle and Late Ming Dynasty, etc. He used to be the director and consultant of Chinese Political Science Society, Chinese Economic History Society, Chinese Archives Society and China Ming History Society. Visiting researcher at the East-West Asia Research Center in Fei Zhengqing, Harvard University, and visiting scholar at Harvard Yanjing Society; Visiting professor, Department of East Asian Studies, Oxford University, UK, and part-time academician of St. Anthony’s College. He is currently a visiting professor at the Institute of History, Guangdong Academy of Social Sciences.

　　Professor Wei Qingyuan, who is currently a visiting researcher at the Institute of History of Guangdong Academy of Social Sciences, devoted his life to the study of Ming and Qing history and academic works. However, in seventy years of age, Wei Lao "changed careers" and wrote novels for ten years. Recently, on the occasion of Wei Lao’s 80th birthday, his first historical novel Zhengde Fengyun-A Biography of Zhu Houzhao, the Emperor of the Dangzi, was published.

　　Joking about history worries experts.

　　Since 2005, there has been a "Ming history fever" in the domestic publishing industry. However, Wei Lao did not launch this 800,000-word Ming Dynasty book to "follow the fashion".

　　"It is said that historical novelists annoy historians." Some ridiculously "wild" books and film and television works are popular in the book market and on the screen, which makes Wei Lao very worried. For example, in a TV series, sourdrang dowager ordered her grandson, Emperor Kangxi, to marry Aunt Su Mala, and named her a princess. The fact is: Aunt Sumala was a maid who came to Manchuria from Mongolia in the early years after Xiao Zhuang. She was at least 40 years older than Kangxi. How could she get married?

　　The wind of popular culture jokes is easy to cause misconceptions to the public. Out of respect for history and the sense of responsibility of a historical researcher, Wei Lao sprouted the idea of writing novels. He believes that research results with academic value are important, but after all, there are not many people reading; If historians have spare capacity, they can write some popular historical works that convey correct knowledge and spread them to the public.

　　Wei veteran’s "Zhengde Fengyun" is regarded as a bold exploration. In this novel, he follows the original development of history and the reasonable filling of literary flesh and blood, depicting all kinds of characters and varied story details centered on Emperor Zhengde.

　　Zhang Hui’s novels excavate the emperor’s abnormal love

　　There were more than 30 emperors in Ming and Qing Dynasties. Why did Wei Lao choose Zhu Houzhao, Emperor Zhengde of Ming Wuzong, as the hero of his first novel?

　　The most famous joke about Emperor Zhengde in folklore is "prince and the showgirl". Zhengde ascended the throne at the age of 14, and during his 16 years in office, he ran amok, spoiled officials, harmed loyalty and robbed women, which led to the crisis of the national government and people’s livelihood at that time.

　　Wei Lao believes that it is not an exaggeration to denounce Zhu Houzhao as a "prodigal emperor", "devil incarnate" and "slut villain". However, for a long time, the description of Zhengde in history books is mostly faceless or bold, which fails to deeply reflect the specific facts of Zhengde and the period of Zhengde. There are still many confusing contradictions and suspense that are difficult to answer hastily. For example, Zhengde’s feelings and sexual orientation are incredible: on the one hand, he frantically searches for and mutilates countless women, including pregnant women, widows and virgins; But on the other hand, he was deeply attached to Liu Liangnv, a married woman who had been taken captive from Taiyuan, until his death. "For women from abuse to rare special pet, this strange abnormal love was set in a person’s body, especially an emperor. What is the psychological secret? "

　　In Zheng De Fengyun, written in the form of Zhang Hui’s novel, Wei Lao launched a macro narrative based on a large number of historical facts, and at the same time tapped the Oedipus complex and abnormal love of Emperor Zheng De with psychological analysis.

　　Chen Jiexian, a famous historian of Qing Dynasty and a visiting professor of history department of Nankai University, commented on the Emperor Zhengde written by Wei Lao, "It is not simply to reprimand him for his dissoluteness and madness, but to go deep into the inner world where the master is not easy to show people, and to write a true Zhengde vividly and completely."

　　However, Wei Lao personally said that his first attempt to write a historical novel may be a failed experiment. But in any case, history is a mirror, from which the subsequent world situation and personnel can be reflected.

Editor: Sun Jie

The summer heat has passed, but the temperature doesn’t mean to drop. If you are still steaming to death in the hot weather after the summer heat, it’s time to go to Pinduoduo to feel the long-lost coolness.

Pinduoduo’s 10 billion subsidy for summer clearance has officially arrived. The highest 260 yuan large-value coupon package is waiting for you to collect, and then you can enjoy a discount on the coupons of active goods, and give you an ice point price in hot summer!

Get the coupon first when you pass by, and you will never lose money when you get the coupon! As low as, the highest straight drop in the whole series!

If you don’t want to miss this ice cream, just click on the link below and enter and choose your baby.

> > > Click here to go to the main venue of the 10 billion subsidy < < <

As usual, I have carefully compiled a list of good things for everyone, all of which are hot-selling products, and I believe there will be something that will make you feel excited.

In terms of mobile phones, I still recommend the 14 series for everyone. This Pinduoduo summer clearance promotion, the price of iPhone 14 series is:

IPhone14, the summer promotion price is as low as!

IPhone14 Pro, the price is as low as summer!

IPhone14 Pro Max, the summer promotion price is as low as!

IPhone 14 is equipped with a 6.1-inch Retina XDR OLED display with original color display, tactile touch and peak brightness of up to 1200 nits. Internally, iPhone 14 still uses A15 bionic chip, but it provides better performance than.

The iPhone14 Pro has a redesigned original deep camera array, which can provide a unique interactive way of "smart island". The 6.1-inch Super Retina XDR display is brighter and has the function of AOD display. Its A16 chip is the first Apple chip based on 4nm technology.

Click on the link below to go to Apple to buy the iPhone 14 series. .

> > > Click here to go to Apple Special < < <

As for the mobile phone, I would like to recommend the official website price of Glory 90,12gb+256gb, and the price of Pinduoduo’s tens of billions of subsidies for summer clearance promotion only needs.

Glory 90 is designed by Jingyue, equipped with a 6.7-inch 3840Hz UHF dimming quad screen, built-in 5000mAh battery, and supports 66W fast charging. At the same time, it is equipped with a 200 million pixel outsole main camera on the image.

Click on the link below to go to HONOR Subsidy Museum to buy Glory 90. .

> > > Click here to go to HONOR Subsidy Museum < < <

Next is a high-end flagship mobile phone, vivo X90, 8GB+256GB official website price.10 billion subsidies, summer clearance, big price promotion, just!

Vivo X90 is equipped with MediaTek Tianji 9200 processor, with self-developed V2 image chip and ultra-wide ice field cooling system, built-in 4810mAh battery, 120W dual-core flash charging support, and 50MP VCS IMX866 main camera.

Click on the link below to go to the OPPO mobile phone subsidy museum to buy vivo X90. .

> > > Click here to go to vivo mobile phone subsidy museum < < <

It’s a good time to officially play games during the summer vacation. Here we recommend a light and shadow wizard 9 game book from HP, official website price.Pinduoduo’s 10 billion subsidies for summer clearance and promotion activities only cost!

This HP Shadow Wizard 9 is equipped with Intel i7-13650HX processor, NVIDIA RTX 4060 graphics card, 16.1-inch 2.5K 165Hz refresh rate screen, 16GB dual-channel 4800MHz memory and 1TB PCIe 4.0 large-capacity solid state drive.

Click the link below to purchase this HP Light and Shadow Wizard 9. .

> > > click here to buy < < <

In addition to playing games with the game book, the console or console is also a good choice. Here, we recommend the limited edition Switch OLED of the legend of zelda: Tears of the Kingdom, the original price of the Hong Kong version in official website, and the subsidy price for the summer clearance in Pinduoduo.

Switch OLED uses a 7-inch OLED screen and a better speaker. The built-in storage space has also been upgraded from 32GB to 64GB, and the bracket at the back of the fuselage is also larger. The battery life is similar to the previous battery life enhanced version.

Click the link below to purchase this limited edition Switch OLED of the legend of zelda: Tears of the Kingdom.

> > > click here to buy < < <

The weather is hot, and mobile phones are more prone to fever. For those who play mobile phones frequently, you need this one plus 27W freezing point heat dissipation back clip, with the original price in official website and a subsidy of 10 billion yuan for summer clearance.

This one-plus-27W freezing point cooling back clip has 27W ultra-high power full of blood, 1800 square mm super-large cooling plate area, brand-new customized double TEC cooling plate 2.0, temperature difference increased by 1.5, high-energy cooling, and direct filling.

Click on the link below to purchase this one plus 27W freezing point cooling back clip.

> > > click here to buy < < <

In summer, many people have the need to store cold drinks. Here we recommend another refrigerator, Xiaomi 606L cross four-door air-cooled frost-free refrigerator (BCD-606WMFSA), the original price of official website, and a subsidy of 10 billion yuan to clear the house in summer.

Xiaomi 606L cross four-door air-cooled frost-free refrigerator supports the water molecular sieve ecological preservation technology, and the moisturizing fresh-keeping drawer is built with an ecological moisturizing film to control the humidity in the drawer and prevent the water loss of fruits and vegetables. At the same time, the fuselage is as thin as 69cm, and the embedded cabinet is not abrupt, and the integrated home space is more free.

Click the link below to buy this millet 606L cross four-door air-cooled frost-free refrigerator. .

> > > click here to buy < < <

It is the most wonderful thing to come to a bottle of iced drinks in summer. Here we recommend 500ml*15 bottles of alien electrolyte water in a full case, with the original price in official website, and a subsidy of 10 billion yuan for clearing the house in summer.

The alien electrolyte water contains 0 sugar and 0 calories, and the electrolyte is more than or equal to ≥200mg/bottle, which helps to maintain the electrolyte balance in the body and keep the body in a good hydration state. In addition, it is specially added with double vitamins, which has the functions of antioxidation and helping protein to metabolize and utilize.

Click on the link below, and you can go to the summer snack night snack to buy 500ml*15 bottles of this alien electrolyte water. . At the same time, there are many summer delicacies, drinks, beer, crayfish and so on in the summer snack special, and you can choose according to your needs.

> > > Click here to go to the summer supper special < < <

As for fruits, I recommend this sunshine rose as a whole string of sunny Wang Putao qingti, with the original price and 10 billion subsidies for summer clearance.

Sunshine Rose Sunny Wang Putao Qingti pulp is full, crisp and sweet, full of juice, irrigated with natural mountain spring water, naturally mature, with higher sugar and sweeter.

Click on the link below, and you can go to the Treasure Fruit Special to buy this whole string of sunny roses, Wang Putao Qingti. . Of course, if you want other fruits, you can also choose them at the special event.

> > > Click here to go to the Treasure Fruit Special < < <

Finally, Wuliangye 52-degree 500ml×1 bottle of Luzhou-flavor liquor, original price in official website.10 billion subsidies, summer clearance and big promotion activities only need,!

Wuliangye has a brand precipitation of more than a century. The brand-new eighth-generation Wuliangye combines the charm and essence of Wuliangye, with a long aroma, mellow taste, sweet entrance, clean throat and just right coordination.

Click on the link below, and you can go to the famous wine special to start with this Wuliangye 52-degree Luzhou-flavor liquor in 500ml×1 bottle.

> > > Click here to go to the famous wine special < < <

In addition to the products recommended by Xiaobian above, there are more welfare benefits waiting for you in this Pinduoduo’s 10 billion subsidy summer clearance promotion activity. Click on the link below to discover more surprises.

> > > Click here to go to the main venue of the 10 billion subsidy < < <

In addition, what you see in the tens of billions of subsidies are genuine and good goods authorized by major brands, and the quality of products is trustworthy, so friends can buy with confidence.

At present, the activity has been hotly started, so friends should hurry to buy it.

　　Cctv news(Reporter wanglili): At 22 o’clock on the evening of October 3, the reporter learned from the Shanxi Taiyuan Epidemic Prevention and Control Office that at 12: 00 on October 12:00&mdash; At 12:00 on the 3rd, 2 local confirmed cases and 5 asymptomatic infected people were added in Taiyuan.

　　Now its activity trajectory is notified as follows:

　　Case 20

　　Female, living at No.98, North Campus of Taiyuan University of Technology, runs a fruit shop in north university of china, and is a close contact of Case 6. On September 30th, jiancaoping district centralized isolation medical observation. On October 1, the test result of nucleic acid was positive, and it was immediately transferred to the Fourth People’s Hospital of Taiyuan for isolation and treatment. After consultation by provincial and municipal experts, it was diagnosed as asymptomatic infection. The initial activity trajectory is as follows:

　　September 25th.

　　At around 7:00, we will purchase goods at Tunhui Fruit and Vegetable Trading Center and then return to north university of china Fruit Shop.

　　September 26th

　　At about 5:40, take a taxi to the Second Hospital of Shanda to accompany my mother;

　　Around 18:00, I didn’t go out after taking a taxi home.

　　September 27th.

　　Around 7:00, take a taxi to the Second Hospital of Shanda to accompany my mother;

　　Around 19:00, I didn’t go out after taking a taxi home.

　　September 28th.

　　At around 7:00, we will purchase goods at Tunhui Fruit and Vegetable Trading Center and then return to north university of china Fruit Shop.

　　September 29

　　At around 6:00, go to Tunhui Fruit and Vegetable Trading Center to purchase goods; At about 8:00, I went to Guangshe Small Food Wholesale Market to purchase goods, returned to north university of china Fruit Store at about 8:30, and returned home at 23:40. After receiving the community notice, I was isolated at home.

　　Case 21

　　Male, lives in Hexi Agricultural Products Market in Wanbailin District, and works in Hexi Agricultural Products Market. Static management was carried out on the evening of October 1, and the nucleic acid test result was positive on October 2, and then it was transported to the Fourth People’s Hospital of Taiyuan for isolation treatment. After consultation by provincial and municipal experts, it was diagnosed as asymptomatic infection. The initial activity trajectory is as follows:

　　September 25th.

　　Around 9:00, ride an electric car to jiancaoping district Rongxing Tianshun Community to supervise the workers to decorate the house;

　　At around 13:00, eat in the small restaurant at the north entrance of the community, and then return to Rongxing Tianshun Community;

　　Around 16:00, I rode an electric car back to Hexi agricultural and sideline products market and didn’t go out after that.

　　September 26th

　　I didn’t go out in Hexi agricultural and sideline products market all day.

　　September 27th.

　　Around 9:00, ride an electric car to the Tianshun Community in Rongxing to supervise the workers to decorate the house;

　　At about 11:00, I rode an electric car back to Hexi agricultural and sideline products market and didn’t go out after that.

　　September 28th.

　　I didn’t go out in Hexi agricultural and sideline products market all day.

　　September 29

　　At around 14:00, ride an electric car to Rongxing Tianshun Community to supervise the workers to decorate the house;

　　Around 18:00, I rode an electric car back to Hexi agricultural and sideline products market and didn’t go out after that.

　　September 30th.

　　At about 11:00, I bought food in the vegetable shop of Hexi agricultural and sideline products market, and then I returned to the shop and didn’t go out.

　　October 1st

　　Around 10:00, ride an electric car to the provincial cancer hospital to see the patient;

　　At about 11:00, I rode an electric car back to Hexi agricultural and sideline products market and didn’t go out after that.

　　Case 22

　　Male, returning (arriving) from outside the province. On September 30th, I took the Z166 train (6 carriages) from Lhasa, changed to the K672 train (14 carriages, No.10 upper berth) in Xi ‘an on October 1st, and changed to the D5342 train (6 carriages, 9F) in Houma on October 2nd, and arrived at Taiyuan South Station. Houma informed me that the nucleic acid test result was abnormal and it was positive in Taiyuan South Station. He was immediately transferred to the Fourth People’s Hospital of Taiyuan for isolation and treatment. After consultation by provincial and municipal experts, it was diagnosed as asymptomatic infection.

　　Case 23

　　Female, living in Xindian Community, jiancaoping district, is the wife of Case 11. September 27th & mdash; I stayed at home on the 30th and never left the community. On September 30th, jiancaoping district centralized isolation medical observation. On October 2, the nucleic acid test results were positive, and they were immediately transferred to the Fourth People’s Hospital of Taiyuan for isolation and treatment. After consultation by provincial and municipal experts, it was diagnosed as a confirmed case (light).

　　Case 24

　　Female, lives in Lanting Xiyuan Community, Jinyuan District, and runs her own shop in Hexi agricultural and sideline products market. On October 3, the nucleic acid test result was positive, and it was immediately transferred to the Fourth People’s Hospital of Taiyuan for isolation and treatment. After consultation by provincial and municipal experts, it was diagnosed as asymptomatic infection. The initial activity trajectory is as follows:

　　September 28th.

　　Activities in Hexi agricultural and sideline products market in Wanbailin District during the day;

　　At about 18:00, samples were taken at the nucleic acid detection point at the west gate of Hexi agricultural and sideline products market;

　　At around 19:00, go to Delicious Zhai Hotel and then return to Hexi Agricultural and Sideline Products Market Store.

　　September 29

　　Activities in Hexi agricultural and sideline products market during the day;

　　At about 17:30, I will pick up my grandson at the nursing point in the west of Lanting Yuhu City, Jinyuan District, and then return to the store of Hexi agricultural and sideline products market;

　　Around 20:00, go to Delicious Zhai Hotel;

　　At around 21:00, samples were taken at the nucleic acid detection point at the west gate of Hexi agricultural and sideline products market, and then returned to the store of Hexi agricultural and sideline products market.

　　September 30th.

　　Activities in Hexi agricultural and sideline products market during the day;

　　At about 20:00, samples were taken at the nucleic acid detection point at the west gate of Hexi agricultural and sideline products market;

　　At around 22:00, go to Liankezheng Clinic in Wanbailin District;

　　At around 22:30, arrive at Delicious Zhai Hotel, and then return to Hexi Agricultural and Sideline Products Market Store.

　　October 1st

　　At around 9:00, go to Delicious Zhai Hotel;

　　At around 13:00, return to the store of Hexi agricultural and sideline products market;

　　At about 19:00, samples were taken at the nucleic acid detection point at the west gate of Hexi agricultural and sideline products market, and then returned to the store of Hexi agricultural and sideline products market.

　　At about 19:50, pick up his grandson at Delicious Zhai Hotel, and then return to his home in Lanting Xiyuan Community, Jinyuan District.

　　October 2 nd

　　At about 10:00, I took my grandson to the nucleic acid detection point in Lanting Xiyuan Community and went to the vegetable shop in Unit 1 of Building 1 of the Community to buy food.

　　Around 16:00, go to the entrance of Building 1 in Lanting Xiyuan Community;

　　At around 19:00, after receiving a call from the epidemic prevention department, they were isolated at home.

　　Case 25

　　Male, living in Tianshun Community, Rongxing, jiancaoping district, a student of jiancaoping district Science and Technology Experimental Primary School, is the son of Case 12. On October 1st, jiancaoping district centralized isolation medical observation. On October 2, the nucleic acid test results were positive, and they were immediately transferred to the Fourth People’s Hospital of Taiyuan for isolation and treatment. After consultation by provincial and municipal experts, it was diagnosed as asymptomatic infection. The initial activity trajectory is as follows:

　　September 26th & mdash; 28th

　　At about 7:30, walk to jiancaoping district Science and Technology Experimental Primary School;

　　Around 11:50, walk home after school;

　　Around 14:40, walk to jiancaoping district Science and Technology Experimental Primary School;

　　Around 18:30, I walked home after school and didn’t go out after that.

　　September 29

　　At about 7:40, my mother rode an electric car to school;

　　Around 11:50; After school, my mother rides an electric car to take me home;

　　At about 14:40, my mother rode an electric car to school;

　　At about 18:30, my mother took it home by electric car after school and didn’t go out.

　　September 30th.

　　At about 8:30, samples were taken at the nucleic acid collection point in Tianshun Community of Rongxing;

　　At about 16:30, I went to school to get books with my mother, and then I returned home and didn’t go out.

　　October 1st

　　Around 14:00, medical observation was concentrated in isolation by the pointed lawn.

　　Case 26

　　Male, living in Xindian Village, jiancaoping district, tested positive for nucleic acid on October 3, and was immediately transferred to the Fourth People’s Hospital of Taiyuan for isolation treatment. After consultation by provincial and municipal experts, it was diagnosed as a confirmed case (light). The initial activity trajectory is as follows:

　　September 27th &mdash; On the 29th, it was mainly in Xindian Village.

　　On September 30, he attended the funeral of the villagers in the same village.

　　October 1st &mdash; I stayed at home on the 3rd.

　　Please report to the local community (village), unit, hotel or local epidemic prevention and control office immediately for those who have been to the relevant key areas and places during the above risk period, and actively cooperate with the implementation of various epidemic prevention and control measures such as isolation observation, health monitoring and nucleic acid detection.

　　Please consciously abide by the epidemic prevention and control regulations, gather less, gather less, have less dinners, do personal protection when going out, and keep a safe social distance. Once suspicious symptoms of COVID-19 appear, go to the nearest fever clinic or designated medical institutions for treatment and investigation. Those who do not truthfully report their personal trips, fail to implement epidemic prevention and control measures according to regulations, and cause the spread or risk of infectious diseases, resulting in serious consequences, will be investigated for legal responsibility according to law.

　　[car home Industry] In two weeks, the automatic transmission industry in China will usher in a major event. Point the coordinates to Yangzhong, Jiangsu, and Hive Yichuang Industrial Park. The first 9DCT automatic gearbox and hybrid powertrain independently developed by local enterprises in China will be officially launched. This indicates that Honeycomb Yichuang "I Era 2.0" will realize industrialization.

　　As the core of Great Wall Motor’s power system, Honeycomb Yichuang’s "I Era" new generation powertrain 4N20 engine and 9DCT/9HDCT automatic gearbox are both mass-produced in Yangzhong Industrial Park. At the same time, Honeycomb Yichuang’s first 3.0L V6 gasoline engine HY6Z30 and the first 9AT/9HAT are also under simultaneous mass production planning. Recently, Zheng Lipeng, vice president of Honeycomb Yichuang, revealed more key information to car home.

　　Many people may be unfamiliar with hives. Honeycomb Yichuang, cultivated by Great Wall Motor for many years, is one of the cores of its supply chain system.

　　In 2018, Great Wall Motor reorganized its parts system, integrating Honeycomb Yichuang (engine, gearbox, electric drive, intelligent steering), Noble Automobile (seat, interior and exterior decoration, rubber, etc.), Jingcheng Engineering (chassis, die casting, equipment, etc.) and Mande Electronics (photoelectric, thermal system, electrification business) successively, participating in market competition and supplying to the outside world. In addition, the power battery industry operates independently with honeycomb energy, and the hydrogen energy industry operates independently with untapped energy and combustion power.

"Honeycomb Easy Creation mainly includes power, transmission, electric drive and intelligent steering business"

　　At present, Honeycomb Easy Creation is mainly located in Baoding, Xu Shui, Tianjin, Yangzhong, Chongqing and Taizhou. In Yangzhong, the project of honeycomb power system, transmission system and electric drive system will be put into production before the end of this year, and the die-casting project of intelligent steering system and Jingcheng Engineering will be completed by the end of this year.

■ The supply system is completely localized.

　　Many years ago, when Great Wall Motor no longer relied on foreign procurement of engines, the automatic gearbox became its breakthrough point, and it did not hesitate to point to 7DCT. Since mass production in 2017, with the huge market of Great Wall Motor, Honeycomb Yichuang 7DCT has become a well-known product, and the market share will exceed 2 million units by the end of this year.

　　Soon, not only the Great Wall, but also many local enterprises in China will enter the 9th gear era.

　　In July this year, the 4N20 engine in the new generation powertrain of the "I Era" was rolled off the assembly line in Honeycomb Yangzhong, and 9DCT and 9HDCT will be put into production in November, followed by DHT dual-motor hybrid special gearbox. In the future, with the completion of new factories in Taizhou, Jiangsu and Yongchuan, Chongqing, Honeycomb Yichuang will establish a perfect gearbox production system throughout the country.

　　Why do you want to do the ninth gear? The purpose is to make the engine more efficient. On the one hand, the efficient range of Honeycomb’s innovative first-generation engine will be wider, and on the other hand, the engine will operate in the efficient area as much as possible through the cooperation of the 9-speed automatic gearbox. In addition to the horizontal 9DCT, Honeycomb Yichuang China’s first vertical 9AT and hybrid system will also be unveiled in the future.

　　Now, the hive can completely not rely on imported parts, the gearbox supply chain is completely localized, and the upstream suppliers are also local and foreign (required to build factories in China). Each component will have different suppliers and can be substituted for each other to maintain the stability of the supply system.

　　The engine and automatic gearbox are only part of the layout of the honeycomb enterprise.

　　In terms of electric drive, Honeycomb is supplied by Euler. Since it was put into production in June, the market has more than 10,000 units, and the flat wire motors at the forefront of the market have already been laid out. The Honeycomb Motor Project Team (the predecessor of Honeycomb Electric Drive) made it clear at the beginning of its establishment in 2012 that flat wire is the future development trend, and in 2015, the first Hairpin drive motor was trial-produced. In Yangzhong, the future production capacity of Hairpin motors will be expanded to 500,000 units/year. At present, honeycomb electric drive has developed 45kW-150kW products, while 200kW products are under development.

　　In terms of steering, Honeycomb turned to independently develop DP-EPS intelligent steering system, which was applied to the latest (|) and Great Wall H9. In the future, Yangzhong will also invest 250,000 sets of annual steering system capacity. Honeycomb turning will also realize foreign matching.

■ Mastering core technologies and opening up cooperation.

　　Undeniably, the supply system of Great Wall Motor has realized "internal circulation" in China. Zheng Lipeng said: "If we really want to have core competitiveness, we must achieve comprehensive control from hardware manufacturing to software design."

　　In Taizhou, the dual clutch module and hydraulic module will be produced independently, which means that all the core components of the automatic gearbox can be controlled by the hive. At the same time, the control software of automatic gearbox is also owned by Honeycomb, and the engine control software will also be independently developed by the end of next year.

　　It is worth noting that turbocharger, transfer case, hydrogen fuel cell air compressor, 70Mpa hydrogen storage bottle, valve body and honeycomb are also laid out, and some production lines are under construction. These are areas that were once monopolized by foreign companies in the past.

　　"When we have the ability to produce key components such as dual clutch modules and hydraulic modules, it does not mean that we will weaken cooperation with companies such as Borgwarner and Schaeffler, which are still the most important partners of the hive." Zheng Lipeng emphasized that the ability of self-production can convince the partners that the hive has mastered many patents in these key areas.

"Gun 2020 2.0T Travel Edition"

　　In Zheng Lipeng’s view, "when others get your new technology and design, they are mostly skeptical, but if we can verify and produce, it will not be like this." It is reported that according to the feedback from users of Great Wall H9 and Gun, it is hoped that the next generation of transfer gears can shift gears dynamically and their performance will be further improved. To this end, the Great Wall has put forward a brand-new design and is talking with suppliers about how to produce it.

　　All kinds of new ideas are based on the demand of product differentiation. Looking back many years ago, China enterprises such as Great Wall were still very weak, and they had no right to speak when talking about cooperation with top suppliers in the world. It was good that the other side was willing to cooperate and provide products. Now, when the procurement demand of the Great Wall is large enough and the market is rich enough, a new concept of positive research and development will be needed to build a competitive advantage.

　　"We don’t have to do everything ourselves. The actual application is external suppliers plus some self-production. The purpose of self-production of key components is to master core technical capabilities and cultivate local supply chains. " Zheng Lipeng said, "We have basically achieved 100% localization of all products."

　　It is expected that the honeycomb enterprises will start to support local enterprises with their own core technologies.

　　In fact, Honeycomb Yichuang has been looking for opportunities for foreign breakthroughs since it confirmed its independence from the Great Wall in 2018. In August 2019, BAIC, Great Wall and SDIC China Merchants (the management company of SDIC Innovation and the second largest shareholder of Honeycomb Energy) signed a strategic cooperation agreement. Since then, BAIC and Honeycomb Yichuang have become closer and closer. In May this year, the new Beijing BJ40 was launched with HY4C20B 2.0T gasoline engine produced by Honeycomb Yichuang. This is the cooperation between two China brand car companies, BAIC and Great Wall, and it is also the result of Honeycomb’s active external support.

"Beijing BJ40 2020 2.0T automatic four-wheel drive urban hunter edition"

　　Before the end of next year, in addition to BAIC, Honeycomb Yichuang will also add four engine customers and two gearbox customers, and the development work is currently underway. In addition, the new customer cooperation information of motors and batteries will be released one after another, and the hybrid special transmission DHT will also support some new forces to build cars in the future.

■ cut in from mixing to create an ecological circle

　　Not long ago, the "Technology Roadmap 2.0 for Energy-saving and New Energy Vehicles" just officially released has been very clear. It is planned that by 2035, the proportion of energy-saving vehicles and new energy vehicles in China will each account for about 50%. This means that the policy orientation confirms the important strategic position of energy-saving hybrid vehicles.

　　At present, the choice of hybrid technology route is not the same in the major automobile markets around the world. In China, the application of P2 and DHT architecture is more prominent. From the perspective of consumer demand, in addition to energy saving and consumption reduction, different consumer groups show diversity in cost performance, power and extreme demand, and the research and development innovation of hybrid technology requires multiple design concepts.

"Honeycomb Easy-to-Create Hybrid System Solution"

　　According to the data, Honeycomb Yichuang has created a hybrid product design concept of power system called "X in One". Where "X" stands for diversified product R&D platform, "in" stands for diversified integration of power system, and "One" stands for flexible product service oriented to customer demand.

　　Zheng Lipeng said that such a platform combination can meet the needs of different user groups.

　　At present, Honeycomb has built 2.0T and 3.0T hybrid engines. Matching 9HDCT and DHT hybrid transmission in transverse structure, matching with 1-speed or 2-speed eAD electric drive axle, can match the honeycomb energy lithium-ion battery (PHEV); Under the vertical structure, it is matched with the 9HAT and DHT hybrid special transmission, and the first gear TOD2 is a high-performance transfer gear for TOD, which can match the lithium ion battery (PHEV).

　　In the longer term, platformization is just the beginning. In the future, based on the platform and resource advantages within the Great Wall Holding System, Honeycomb Yichuang will strive to build a full-spectrum automotive powertrain technology ecology covering traditional-hybrid-pure electric-hydrogen fuel power. Honeycomb Yichuang will cooperate with Honeycomb Energy and Unprovoked Energy to build a full-spectrum business ecosystem of future automobile power system around the future automobile power system.

　　By 2025, Honeycomb will achieve an engine capacity of 1.95 million units, a gearbox capacity of 2 million units, an electric motor drive capacity of 550,000 units and a power battery capacity of 100GWh h..

Editor’s summary:

　　In recent years, it is a trend that the excellent parts enterprises cultivated by the automobile factory are gradually independent, but it is not easy to really get rid of the backer to achieve external supply. Honeycomb Easy Creation, Honeycomb Energy, Unprotected Energy, and three other independent parts enterprises cultivated by the Great Wall are all worthy of in-depth study.

　　The breakthrough of honeycomb enterprises began with engines and automatic gearboxes, and strengthened the route of hybrid, pure electric and hydrogen energy. Nowadays, Honeycomb is easy to create, including Honeycomb Energy and Unprotected Energy. The total number of employees in the world has reached 18,000. Team management may be a relatively difficult problem for Honeycomb. In fact, Wei Jianjun, the chairman of Great Wall Motor, has been promoting the reform, and Honeycomb is also following up the establishment of combat units and mechanisms, and implementing the concept of coordinated operations. In Zheng Lipeng’s eyes, the Great Wall provides a very clean platform for the right people to do the right things, without any professional background. As long as you have the ability and can respond quickly, you will have a chance to rise. (Text/car home Liu Honglong)

　　Trump shouted "It’s easy to win!" While heading for the "trade war road", the end of the road is unemployment, losses, government tax losses and the reduction of cheap goods.

　　Trump hoisted a "trade war melting pot" and said that "the job opportunities brought by the trade war will be caught while it is hot!" (Comics are all from cagle Comics website)

　　Trump fired a shell of "increasing steel import tariffs", but what he got was that he could not increase employment, revenge from allies, rising costs and domestic political influence.

　　In order to "give priority to the United States" and "make the United States great again", US President Trump really took pains. Frequent lifting of the trade stick is aimed at forcing the "opponents" in their eyes to sit at the negotiating table and maximize the interests of the United States. Facing the American people and enterprises, he has a firm tone and promises to realize the prosperity of the United States; In the face of allies and "opponents", he expressed his emotions and demanded to realize the interests of the United States. However, the businessman president with the aura of "the art of trading" on his head doesn’t seem to realize that it may work in business, but it doesn’t work in international relations and trade. Whether at home or abroad, under the leadership of Trump, the United States and "unreliable" began to go hand in hand.

　　trade warfare

　　Can manufacturing return?

　　"Buy American goods and hire Americans!" This is the goal that US President Trump has repeatedly emphasized. Revitalizing the American real economy is also considered to be one of the important reasons why the United States is bent on provoking trade frictions around the world. However, as the United States continues to overweight in the trade war, what is the result?

　　Remember Harley, the motorcycle manufacturer who announced his departure because of the trade war and caused Trump’s anger? Harley’s quarterly report shows that its motorcycle shipments fell by 11.3% in the second quarter. The company’s operating profit margin in 2018 was forced to drop from 10.5% to 9%&mdash; 10%。 In addition, according to the latest news, the Harley-Davidson motorcycle factory in northern Kansas is about to close, taking the first step to transfer production. Harley is currently building a new factory in Thailand, and plans to transfer more production to India, Brazil and Thailand to save costs.

　　Harley is certainly not the only American company that is complaining. BMW, General Motors and Whirlpool all expressed their dissatisfaction.

　　According to Fortune magazine, BMW announced that it would increase the sales price of two American-made SUVs in China, which is the latest sign of the impact of Trump’s trade war. According to the Financial Times, analysts said that import tariffs are "the main threat to industry profits" and warned that the losses caused by tariffs to BMW and Daimler may reach 4% to 5% of the profits in 2019. BMW and Daimler invested a lot of money to set up factories in the United States, and now they are affected by the trade war provoked by the United States, which is ironic.

　　General Motors and home appliance giant Whirlpool have also lowered their performance expectations. According to the report of the Nihon Keizai Shimbun, there are voices in the financial sector that are worried about the investment willingness of enterprises and the shrinking of personal consumption. The US economy remains strong at present, but the trade war may lead to a decline in investment and consumption, thus expanding the blow to corporate performance and casting a shadow over the real economy.

　　Apple has just become the first technology company with a market value of more than $1 trillion. However, even apples began to cry out for pain. According to the website of Bloomberg News, Apple submitted a report to the US Securities and Exchange Commission: "Tariffs may increase the cost of the company’s products and make them more expensive, thus reducing the competitiveness of products. Political uncertainty surrounding international trade disputes and protectionist measures may also have a negative impact on consumer confidence."

　　"Buying American goods" is difficult to achieve, and "hiring Americans" has become "a mirage".

　　Calvin Dooley, CEO of the American Chemical Council, predicted that a 25% tariff would "have a devastating impact on American chemical manufacturers". Many American companies have warned that if the situation is not alleviated, it may have an impact on the economy and lead to a decrease in jobs.

　　In the smoke of the trade war, Eric Gasetti, the mayor of Los Angeles, led an emergency delegation to visit Asia. There is a simple reason. According to the website of American Consumer News and Business Channel, with the White House threatening to impose higher tariffs on China goods worth $200 billion, many American port managers are preparing for the possibility of cancellation of shipments and unemployment. The ports of Los Angeles and Long Beach are estimated to provide nearly 1 million jobs for the whole of Southern California.

　　This is still the beginning. According to the data of the Peterson Institute for International Economics in the United States, if the United States really imposes a 25% tariff on cars around the world, 195,000 American workers will be in the range of 1-mdash; Unemployment within three years, and in the case of other countries taking countermeasures, the situation will be even worse: the United States will lose about 624,000 jobs.

　　inflation of prices

　　Can you satisfy the people?

　　"American consumers have begun to feel the sting of rising costs." CNN reported that.

　　Erin Ennis, Senior Vice President of u.s.-china business council, said: "About half of the goods from China need to face higher tariffs. The increased cost will be transmitted to American consumers and will affect the wallets of most Americans. " The British Times website reported that.

　　From Coca-Cola to RV, from toys to clothing, the storm of price increase has been thundering.

　　CNN reported that Coca-Cola has raised the price of carbonated drinks because the recent 10% tariff on imported aluminum made the production cost of Coca-Cola cans higher. CEO James Quincy admits that the price increase is "destructive" but necessary.

　　According to the website of The Wall Street Journal, Michael Harpy, CEO of Winnebago Industries, an RV manufacturer, said that due to the recent price increase of some products, the company began to consider raising prices. Although the company did not want to disclose its price increase, it said that in order to cut costs, it had made changes, such as modifying the floor design of the RV.

　　Toys will soon become the "hardest hit". Among the $200 billion of goods to be exported to the United States, including $12.2 billion of children’s toys. The United States is the world’s largest toy consumption market, while China is the world’s largest toy production base. According to the data provided by Guangdong Toy Association, in 2017, 28.8% of China’s toys were exported to the United States, and 80% of the products in the American toy market were made in China.

　　Zhou Shijian, a senior researcher at the China-US Relations Research Center in Tsinghua University, said that the $200 billion of Chinese-made consumer goods accounted for too much, and the substitutability was very limited. If the tax is really increased, most consumers in the United States can immediately feel that "as soon as it is announced, the prices of consumer goods in the United States will rise."

　　The report on the British Science News website quoted Rick Helfenbein, president of the American Federation of Clothing, Footwear and Socks, as saying that Trump imposed tariffs on China products imported from the United States, which led China to impose retaliatory tariffs on goods exported from the United States, which was equivalent to imposing a huge Trump tax on American workers, consumers and the American economy.

　　Joseph Stiglitz, a Nobel Prize winner and a professor at Columbia University, also believes that Trump’s move to start a full-scale trade war with China will lead to "tax everywhere", and the substantially increased costs will be borne by ordinary people, and the poorest class in the United States will suffer the heaviest blow.

　　"These punitive tariffs will be passed on to American consumers and offset all the positive achievements made by the American economy in recent months. There is no better example of hurting yourself in order to vent your anger. " Matthew Shea, CEO of the National Retail Federation, said.

　　Reduce the deficit

　　Can it make America more prosperous?

　　Reducing the US trade deficit is one of Trump’s promises, which is also an important reason for the Trump administration to provoke a trade war.

　　Chen Chenchen, a researcher at Chongyang Financial Research Institute of Renmin University of China and deputy director of the Macro Research Department, pointed out that since Trump took office, he has never given up his deep-rooted policy stance since the 1980s &mdash; &mdash; By grasping the bottom line of the transaction and shrewd negotiation, we will get back all the jobs, industries, market opportunities and trade benefits that belong to the United States. He wants to replace rules with absolute interests and global considerations with absolute American priority. The "fair trade" that Trump wants to achieve most is the lowest-level trade with the greatest American interests as the core. Compared with the previous US government, it is the "zero-sum experience" in the business world that dominates the trade policy thinking at the core of American power.

　　However, almost all analysts believe that it is impossible for him to honor this promise.

　　According to the latest data from the US Department of Commerce, in June, the US trade deficit reached US$ 46.3 billion, a sharp increase of 7.3% over the previous month and the first expansion in four months. Moreover, this deficit data is also the largest data in 19 months. In other words, the current US trade deficit is even higher than when Trump came to power, and it has reached the highest level.

　　I don’t know if Trump will feel a little embarrassed. However, neither the media nor experts are surprised.

　　The Washington post website reported that economists thought it was wrong for Trump to focus on reducing the trade deficit. The only way to really reduce the trade deficit is to let Americans buy less. They believe that Americans have not "suffered" in trade: Americans get cheaper goods from abroad, and most of the dollars flowing to other countries return to the United States in the form of foreign investment or the purchase of American bonds. They stressed that the Trump administration’s tax increase on China products is unlikely to reduce the trade deficit, because Americans will still buy all these goods with tax increase, so enterprises may adopt two solutions: one is to buy goods with tax increase, and the other is to buy from other countries.

　　Kimberly Ann Elliott, a visiting researcher at the Center for Global Development in the United States, pointed out in an article published on the American World Political Review website that Trump did not seem to understand three basic facts about trade policy: first, trade policy could not defeat a wide range of macroeconomic forces; Secondly, the main impact of trade policy is to re-layout the economy; Third, trade policy is far more complicated today than in the past.

　　Lawrence summers, a professor at Harvard University and former Treasury Secretary, wrote an article for the Financial Times website, which also believed that Trump put offensive trade policy at the core of economic governance, which was problematic. Most economists agree that the adjustment of trade policy is unlikely to play a significant role in promoting employment or GDP growth, and loosening trade can promote the prosperity of the United States more than manipulating trade.

　　wield a club (at sb)

　　Can America be great again?

　　"Let America be great again!" This is Trump’s campaign slogan and Trump’s ultimate goal. However, so far, the various practices of the Trump administration have caused widespread doubts.

　　"Trump is depriving the United States of what makes it great." The title of Washington post’s article is simple and direct. The article points out that after World War II, the foundation of American prosperity is the scientific and technological breakthrough promoted by a powerful innovation system. The innovation policy of the United States has been successfully imitated in Europe and Asia, and it has also been imitated by China in recent years. Now, Trump has launched a trade war with China, with the purpose of slowing down the rise of China’s science and technology, but in fact, he has gone astray and is doomed to failure. Instead, the United States should do what it does best &mdash; &mdash; Innovate at home and trade with other countries in the world, so as to keep America prosperous.

　　Washington post columnist Robert samuelson recently published an article on the website of Japan Times, which also pointed out that Trump’s campaign slogan "Make America Great Again" brought an illusion that we can still achieve prosperity by pursuing isolationism. The United States was once "great", but it was achieved by actively participating in international affairs through military alliances and trade policies.

　　Once upon a time, the United States was a well-deserved leader of the western world. However, nowadays, the mentality of Western allies towards the United States may only be described as "bitterness".

　　At the end of July, an international conference against the Trump administration’s trade war was held in Geneva, Switzerland. The participants were all the closest allies of the United States: Japan, South Korea, Canada, Mexico and European Union countries. The reason why these countries are rallying to "resist the United States" is because the investigation on whether imported cars and parts threaten the national security of the United States, which began in May this year, may be completed in August, and the White House is likely to impose a 25% punitive tariff on all imported cars and parts. The German financial network stressed that the message of the Geneva gathering was the EU’s "distrust of Trump’s commitment". German newspaper frankfurter allgemeine zeitung commented that Trump wants to destroy the world order, so what? Countries will unite to protect international organizations and international rules.

　　Former US Deputy Secretary of State richard armitage wrote in the Japanese Yomiuri Shimbun that Trump publicly claimed to make a deal without showing his cards to others. This technique may be effective in business, but it won’t work in diplomacy. Most foreign relations of the United States have been weakened by Trump’s obvious lack of credibility diplomacy, and allies’ trust in American leadership is declining.

　　Washington post’s website article bluntly pointed out that Trump values his pride, his demand for attention, and his ability to create disasters &mdash; &mdash; If he needs to give a heavy blow to the western alliance to convince himself that he is smarter than all his predecessors, then he will not hesitate to do so.

　　Chen Chenchen, a researcher at Chongyang Financial Research Institute of Renmin University of China and deputy director of the Macro Research Department, pointed out that in Trump’s policy thinking, allies who "take advantage of the United States" are not trustworthy. Only through shrewd foreign policy negotiations, including taxation of allied products, will they "have excellent allies again".

　　America’s image has been damaged. The article on the website of the Brookings Institution in the United States directly calls the United States "a rogue superpower" and "actively, powerfully and thoroughly seeks its own interests".

　　Threaten and blackmail

　　Can America be a winner?

　　"The trade war is very simple. Winning is easy. " This is Trump’s judgment.

　　"Trump believes that trade is a &lsquo; Zero-sum game &rsquo; . He believes in trade wars &lsquo; It’s easy to win &rsquo; . He launched a trade war against many countries in order to force them to sit at the negotiating table. " Washington post website reported that.

　　According to this logic, the Trump administration recently played a "combination boxing". The National Defense Budget Act of 2019 just passed by the US Congress directly positions China as a long-term strategic opponent; The Trump administration ordered the US Department of Commerce to put 44 China enterprises and institutions on the export restriction list for technical blockade on the grounds of "significant risks to US national security"; The Trump administration also threatened to impose a 25% import tariff on China’s 200 billion products.

　　However, not many people believe that the United States can easily win the trade war.

　　The CNN report quoted Phil Levy, an expert of Chicago Global Affairs Committee, as saying that raising the tax rate on goods from China is consistent with the President’s strategy of continuously putting pressure on China. There seems to be a feeling among members of the Trump administration that as long as you hit China hard enough, China will give in. However, Levy said, "There is no evidence to prove this."

　　Martin wolf, chief economic commentator of the Financial Times, pointed out that the adoption of "Section 301" by the United States against China sometimes seems to be aimed at forcing China to eliminate its trade surplus with the United States, sometimes seems to be aimed at preventing the "Made in China 2025" plan, and sometimes seems to be aimed at correcting China’s compulsory technology transfer. The first goal is ridiculous, the second goal is not negotiable, and the third goal is difficult to achieve.

　　The Australian Sydney Morning Herald website article believes that in the economic war between the United States and China, Trump adopted the ancient weapon of the 17th century mercantilist era &mdash; &mdash; Tariffs, and China took out the weapons of the 21st century &mdash; &mdash; Renminbi. China’s choice of weapons is more powerful, because China’s investment activities around the world are huge and growing rapidly, which is warmly welcomed by people.

　　Jeffrey Sachs, an American economics professor, and a group of enlightened American scholars he represents believe that the United States’ efforts to curb the rise of China and the development of science and technology by means of blocking trade wars are "doomed to failure".

　　The American media believe that the Trump administration may have used Nixon’s "madman theory". It means that opponents are cautious because they suspect that the president of the United States is unpredictable, occasionally reckless and possibly as dangerous as madness. However, the article on Washington post’s website starts with "&lsquo; Madman theory &rsquo; It will not help Trump win the trade war. It is pointed out that it is good for both China and the United States to retreat from the edge of the trade war. However, this requires cooperation rather than conflict between the two sides. The self-righteous "madman theory" needs to give way to a calmer head.

　　Our reporter Zhang Hong

CCTV News:April 8th is the International Day for the Protection of Rare Animals. We walked into Jiangcheng County, Pu ‘er, Yunnan Province, one of the habitats of Asian elephants, to see the activities of local Asian elephants.

Early in the morning, the reporter followed the Asian elephant monitoring team to the Manlao River in Dashujiao Village, Kangping Town, Jiangcheng County. According to the staff, there were 42 wild Asian elephants in this area recently.

In view of the shortage of food for elephants in winter, corn, sugar cane, bananas, etc. are specially planted in some specific areas for elephants to eat. These places are also called "elephant canteens". However, at this time, corn and sugarcane have just entered the cultivation period, and there is relatively little food in the wild, which leads to more frequent activities of elephants entering the village and is prone to injury accidents. Therefore, the local people deliberately artificially feed at the entrance of some villages.

In addition to feeding the Asian elephants well, the daily focus of the staff is to monitor the range of activities of the Asian elephants.After locating the elephant activity area, the staff immediately controlled the roads along the way and placed warning signs. At the same time, they issued early warnings through WeChat group, monitoring and early warning platform and village broadcasting, and tracked the monitoring activities with drones.

Yunnan Shuangbai: Photographers shot a lot of rare green peacock videos.

Green peacock is a national first-class protected wild animal, mainly distributed in Yunnan Province and some Southeast Asian countries. At present, the number in China is only between 550 and 600. Green peacocks are timid and difficult to approach, so there are few related videos except a few pictures taken by infrared cameras. Recently, photographers have been crouching for 6 days, shooting a large number of green peacock videos with a 360-degree panorama camera.

In the picture, these green peacocks are foraging by the river bed. It’s the breeding season of green peacocks. During the period of crouching, the photographer photographed that these green peacocks sometimes play, sometimes take a sand bath in the river valley, and sometimes unfold a long tail screen.

Gu Bojian, a teacher at the School of Ecological Environment of Ningxia University: "There are both adult birds and adult birds in the picture. The male green peacock of an adult bird has a shorter tail screen than that of an adult bird. This season is the breeding season for green peacocks. The males have long tail screens, and the feathers in other parts of their bodies are also the most glamorous. Green peacocks can get rid of parasites and keep their feathers bright through sand bath. "

According to experts, this group of green peacocks in front of us was photographed by the infrared camera of the Management and Protection Bureau of Dinosaur River State Nature Reserve in May last year. At that time, they were still chicks with gray-black feathers. After nearly a year, these green peacocks have grown bright feathers and long tail screens.

Wang Sibeng, Director of the Management and Protection Bureau of Dinosaur River State Nature Reserve in Shuangbai County: "As the only original peacock population in China, there are about 550&mdash; 600, all distributed in Yunnan Province. According to the monitoring data of the nature reserve, there are about 360 native green peacocks in Shuangbai County, accounting for more than half of the national population. "

These pickup trucks to be launched in 2020 can be called amazing. Some of them are from established manufacturers such as Ford, RAM, Chevrolet and GMC. Let’s take a look at these pickup trucks.

2020 Ram 1500 Built To Serve edition

The 2020 Ram 1500 Built To Serve edition will release 1,500 vehicles on November 11th, 2020 to commemorate the US military. The body of the special edition adopts a unique appearance, such as the American flag decal on the side of the container, and the special logo of Built to Serve can be found in the interior and appearance.

Ford F-150 SVT Raptor High Performance Edition

There have been rumors before that the Ford F-150 Raptor will be equipped with a 5.2-liter supercharged V8 engine with a maximum power of 700 horsepower on the Mustang GT500. This wish of Raptor lovers has finally come true, and the high-performance version of the Ford F-150 SVT Raptor is expected to be delivered in late 2020 or early 2021.

2020 Ram Rebel TRX Hellcat

In fact, the high-performance version of SVT Raptor above is a response to this performance pickup truck of Ram. The pickup truck also uses V8 engine, and its maximum horsepower will be greater than 700 horsepower. The car has been confirmed to be delivered in the third quarter of 2020, and it will become the most powerful version of Ram 1500 so far and one of the powerful competitors of F-150 Raptor in the future.

2020 Hennessy Ranger VelociRaptor

Hennessy, a refitting company, is civilized because of refitting American muscle sports cars. Their GT Venom is the fastest mass-produced car on the earth, beating Bugatti Chiron at a speed of 427 km/h.. And the Ford Ranger VelociRaptor, which will be launched in 2020.It will be a hybrid of Ford Ranger and F-150 Raptor, equipped with a 350-horsepower 2.3-liter EcoBoost four-cylinder engine, and the basic version will start at $64,950 (about RMB450,000).

2021 Chevrolet Sorod HD Carhartt Special Edition

The 2021 Chevrolet Sorod HD Carhartt Special Edition can be said to be one of the very popular special edition trucks, which was previously unveiled at SEMA 2019. Carhartt is an American tooling brand, which is believed to be familiar to hipsters. This pickup truck built by Chevrolet and Carhartt is also hipster. The car uses Carhartt’s gold details and badges, and is matched with Z71 off-road kit, including double-tube shock absorber, ramp control device and lower fender. The car will be launched in autumn 2020.

2020 Hennessy Maximus 1000 Jeep Gladiator

This car is Hennessy’s product, but the other protagonist has become Jeep, which is precisely because it is equipped with a 6.2-liter supercharged Hellcat V8 engine.This Jeep gladiator pickup truck will have nearly 1000 horsepower.The acceleration time of 0-96km is 3.9 seconds. It sells for as much as $225,000. Even Hennessy himself said that this speed-up performance was crazy.

2020 GMC Sierra Elevation edition

GMC Sierra Elevation has not yet announced its release date. This pickup truck has professional-grade design, exquisite appearance and excellent configuration, including 110V car power socket, electrically controlled rear door, dark privacy glass, LED front fog light, and a 7-inch media touch screen.

In 2020, Navarra N-TREK Warriors were produced.

The 2020 Navarra N-TREK Warrior version is as good as the Silverline and Black Edition versions launched last year. It is based on a brand-new double-row model, which has been improved in configuration and appearance, such as blackened body design, 18-inch wheels, lower enclosure with orange decoration, front grille and fog lights. The power part is equipped with a 2.3L twin-turbo diesel engine with a maximum power of 188 HP. The new car will be delivered in early 2020.Unfortunately, this limited edition model will only be sold in Australia.

2021 Jeep gladiator military pickup truck

This time Jeep and AM General cooperated to manufacture the "Gladiator" military pickup truck, and the release date was the second half of 2020. The completed Jeep Gladiator will be directly adopted by the US Army, which will be the first time Jeep has returned to the US military in decades. It will become the most expensive and powerful pickup truck used by the U.S. Army, and will become the personnel transport vehicle, command vehicle or special equipment vehicle of the Army.